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Abstract 
Nolan John Hoffman 
 
THE EFFECTS OF CHROMIUM ON SKELETAL MUSCLE 
MEMBRANE/CYTOSKELETAL PARAMETERS AND INSULIN SENSITIVITY 
 
A recent review of randomized controlled trials found that trivalent chromium 
(Cr3+) supplementation significantly improved glycemia among patients with 
diabetes, consistent with a long-standing appreciation that this micronutrient 
optimizes carbohydrate metabolism. Nevertheless, a clear limitation in the 
current evidence is a lack of understanding of Cr3+ action. We tested if increased 
AMP-activated protein kinase (AMPK) activity, previously observed in Cr3+-
treated cells or tissues from Cr3+-supplemented animals, mediates improved 
glucose transport regulation under insulin-resistant hyperinsulinemic conditions. 
In L6 myotubes stably expressing the glucose transporter GLUT4 carrying an 
exofacial myc-epitope tag, acute insulin stimulation increased GLUT4myc 
translocation by 69% and glucose uptake by 97%. In contrast, the 
hyperinsulinemic state impaired insulin stimulation of these processes. 
Consistent with Cr3+’s beneficial effect on glycemic status, chromium picolinate 
(CrPic) restored insulin’s ability to fully regulate GLUT4myc translocation and 
glucose transport. Insulin-resistant myotubes did not display impaired insulin 
signaling, nor did CrPic amplify insulin signaling. However, CrPic normalized 
elevated membrane cholesterol that impaired cortical filamentous actin (F-actin) 
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structure. Mechanistically, data support that CrPic lowered membrane cholesterol 
via AMPK. Consistent with this data, siRNA-mediated AMPK silencing blocked 
CrPic’s beneficial effects on GLUT4 and glucose transport regulation. 
Furthermore, the AMPK agonist 5-aminoimidazole-4-carboxamide-1-ß-D-
ribonucleoside (AICAR) protected against hyperinsulinemia-induced 
membrane/cytoskeletal defects and GLUT4 dysregulation. To next test Cr3+ 
action in vivo, we utilized obesity-prone C57Bl/6J mice fed a low fat (LF) or high 
fat (HF) diet for eight weeks without or with CrPic supplementation administered 
in the drinking water (8 µg/kg/day). HF feeding increased body weight beginning 
four weeks after diet intervention regardless of CrPic supplementation and was 
independent of changes in food consumption. Early CrPic supplementation 
during a five week acclimation period protected against glucose intolerance 
induced by the subsequent eight weeks of HF feeding. As observed in other 
insulin-resistant animal models, skeletal muscle from HF-fed mice displayed 
membrane cholesterol accrual and loss of F-actin. Skeletal muscle from CrPic-
supplemented HF-fed mice showed increased AMPK activity and protection 
against membrane cholesterol accrual and F-actin loss. Together these data 
suggest a mechanism by which Cr3+ may positively impact glycemic status, 
thereby stressing a plausible beneficial action of Cr3+ in glucose homeostasis.  
 
 Jeffrey S. Elmendorf, Ph.D., Chair 
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Chapter I.  Introduction 
Humans have evolved to fight starvation. It is ironic that food has become 
modern man’s foe contributing to the increasing worldwide prevalence of obesity 
and type 2 diabetes (T2D). Despite enormous medical progress in infectious 
diseases leading to a dramatic increase in human life expectancy, for the first 
time we are witnessing a reversal of this trend.  This is mainly being driven by 
non-infectious diseases including diabetes, cardiovascular disease and cancer. 
Overnutrition and lack of physical activity in the developed world have 
contributed to the growing incidence of obesity and T2D, which have now 
reached epidemic proportions. According to the United States Centers for 
Disease Control and Prevention 2011 National Diabetes Fact Sheet (1), 25.8 
million Americans and 79 million American adults now have diabetes and pre-
diabetes, respectively. T2D accounts for over 90% of those afflicted with 
diabetes. Diabetes has become a major healthcare and economic burden in the 
United States and worldwide with an estimated total annual cost of $174 billion in 
the United States in 2007. As one of the world’s fastest growing chronic 
diseases, diabetes is a leading cause of heart failure, kidney failure, stroke, lower 
limb amputations and blindness in adults (1). Importantly, there is also a hidden 
burden whereby diabetes can lead to other chronic diseases such as cancer, 
heart disease and Alzheimer’s disease.   
Insulin resistance is a well-recognized pathophysiological feature of pre-
diabetes and T2D.  Insulin resistance is known to drive the progression of T2D 
and has been found to be highly correlative with cardiovascular risk factors that 
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often contribute to morbidity in T2D patients (2). A comprehensive understanding 
of the cellular and molecular mechanisms contributing to insulin resistance has 
not been deciphered. However, it is well-appreciated that nutrient excess and 
obesity due to overeating and lack of physical activity predispose individuals for 
insulin resistance and T2D. While new drugs continue to be introduced and have 
shown some promise for patients, these strategies as a whole are not effectively 
curbing the worldwide epidemic. This is mainly due to the complexity of insulin 
resistance and adaptable nature of obesity.  For example, when a person goes 
on a diet and reduces energy intake, this can be accompanied by a 
compensatory reduction in whole body energy expenditure (3). The shift towards 
a positive energy balance during the progression of obesity not only involves an 
increased energy intake, but also a concomitant lack of physical activity to utilize 
this excess energy (3). Achieving patient compliance with recommended 
programs involving increased physical activity and reduced energy intake 
remains a major obstacle in curbing the obesity and T2D epidemics. Therefore, it 
is crucial to continue dissecting the cellular and molecular mechanisms involved 
in insulin resistance to identify new drug targets of therapeutic interest and 
develop novel strategies for the treatment and/or prevention of obesity and T2D. 
While the complex links between obesity and insulin resistance are still 
incompletely understood, increased levels of glucose, insulin and fatty acids 
(FAs) have been shown to negatively impact insulin sensitivity in both in vitro and 
in vivo experimental models (4-15). For example, high levels of glucose and 
lipids have been shown to prevent the ability of insulin to activate key signaling 
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intermediates resulting in insulin resistance (5, 6, 9). Interestingly, studies have 
demonstrated that pathophysiologically-relevant nutrient toxicity can result in 
insulin resistance without altering key insulin signaling intermediates (7, 8, 13, 
16). Collectively, several studies have established membrane and cytoskeletal 
derangements (i.e. alterations in the plasma membrane (PM) lipid environment 
and/or cellular cytoskeletal structure) as key distal aspects of insulin resistance 
that can impair insulin sensitivity independent of insulin signaling abnormalities 
(7, 8, 10, 17-21). Interestingly, trivalent chromium (Cr3+) has been shown to 
positively impact GLUT4 regulation by lowering PM cholesterol (22-24). Cr3+ is a 
micronutrient that has been appreciated to be beneficial for optimal glucose and 
lipid metabolism since the 1950s. However, whether Cr3+ can protect against 
membrane cholesterol accrual and whether this prevents cortical filamentous 
actin (F-actin) loss and GLUT4 dysregulation remains unknown. 
Building upon fundamental findings in the field presented next, my thesis 
research focused on determining the effects of Cr3+ on skeletal muscle 
membrane/cytoskeletal parameters and insulin sensitivity. The following 
introductory sections will highlight insulin-regulated glucose homeostasis, GLUT4 
regulation by insulin, insulin resistance, Cr3+, and AMP-activated protein kinase 
(AMPK).  
 
I.A. Insulin-Regulated Glucose Homeostasis 
 Insulin is a pancreatic hormone produced by β-cells in the pancreatic islets of 
Langerhans. Insulin regulates a plethora of cellular functions in many tissues 
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throughout the body. A primary function of insulin entails the regulation of post-
prandial glucose homeostasis. In the post-prandial state, an elevation of blood 
glucose triggers release of insulin from β-cells. Once released into the 
bloodstream, insulin acts on the adipose tissue, skeletal muscle and liver to clear 
excess circulating glucose and restore glucose homeostasis. Insulin acts on the 
liver to inhibit hepatic glucose output by turning off glycogenolysis and 
gluconeogenesis. In adipose tissue and striated muscle (i.e. skeletal and cardiac 
muscle) insulin signals to stimulate glucose transport out of the bloodstream and 
into these target tissues. The combined effects of insulin on suppressing hepatic 
glucose output by the liver and stimulation of glucose uptake into adipose tissue 
and skeletal muscle are essential in maintaining whole body glucose 
homeostasis. 
 In adipose and striated muscle tissues, insulin-mediated glucose transport is 
achieved by the ability of insulin to stimulate the redistribution of the insulin-
responsive glucose transporter GLUT4 from intracellular pools to the PM (17, 25-
27). In the absence of insulin, GLUT4 primarily resides in intracellular membrane 
pools. Upon insulin binding to the insulin receptor on the surface of muscle and 
fat cells, insulin triggers a signaling cascade that stimulates an increase in the 
exocytosis rate of GLUT4-containing vesicles. These complex trafficking events 
orchestrated by insulin populates the PM with GLUT4 to allow glucose transport. 
The inability of insulin to properly stimulate glucose transport into muscle/fat and 
inhibit hepatic glucose output, termed insulin resistance, is a central feature of 
obesity, pre-diabetes and T2D. Insulin resistance initially results in glucose 
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intolerance, and the hyperinsulinemic response from the pancreatic β-cells 
immediately compensates to account for the reduced peripheral sensitivity to 
insulin action. While increased insulin secretion from the β-cells can be effective 
in maintaining blood glucose levels over time, this hyperinsulinemia and insulin 
resistance can lead to β-cell expansion and eventual exhaustion/death. Once the 
remaining β-cells can no longer secrete sufficient insulin to maintain glucose 
homeostasis, blood glucose levels increase indicating progression of insulin 
resistance to frank T2D. 
 At the cellular and molecular levels, insulin resistance is very complicated and 
involves many different mechanisms varying between different tissues. In 
adipose tissue and skeletal muscle, one certain definition of insulin resistance is 
the failure of insulin to properly recruit, mobilize and insert GLUT4 into the PM to 
stimulate glucose transport in the setting of normal GLUT4 protein expression. 
Together these two tissues account for over 90% of post-prandial glucose 
disposal (28). The complex derangements observed in insulin resistance stress 
the importance for efforts to dissect these mechanisms of GLUT4 dysregulation 
to develop new drug targets and therapeutic strategies for the treatment and/or 
prevention of insulin resistance and T2D. While a complete understanding of how 
insulin regulates GLUT4 translocation to the PM and glucose transport does not 
yet exist, significant advances have been made to help us understand the actions 
of insulin how these processes become deranged in insulin resistance. 
 The focus of this thesis research was to dissect membrane/cytoskeletal 
parameters of skeletal muscle insulin sensitivity altered in insulin resistance and 
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determine the mechanisms amendable to Cr3+ action. This research is primarily 
focused on skeletal muscle, as this tissue is responsible for a large majority of 
post-prandial glucose disposal (29) and is regarded as a major site of insulin 
resistance (28). Therefore, the following sections and subsections will provide a 
pertinent outline and analysis of our current state of knowledge regarding insulin 
regulation of glucose transport and insulin resistance, primarily in skeletal 
muscle. Expanded information on hepatic and/or adipocyte insulin action can be 
found in several detailed reviews on these topics (30-32). While skeletal muscle 
will be the major focus of the background and research outlined in this thesis, it is 
important to note that skeletal muscle is by no means the only tissue involved 
with maintenance of glucose homeostasis and development of insulin resistance.       
 
 I.B. Signaling, Cytoskeletal and Membrane-Based GLUT4 Regulation 
 Solving how insulin regulates glucose transport into skeletal muscle and 
adipose tissue remains a fundamental challenge in biology and a significant 
issue in medicine. A central feature of this process is the coordinated 
accumulation of the glucose transporter GLUT4 into the plasma membrane. New 
signaling and cytoskeletal mechanisms of insulin-stimulated GLUT4 exocytosis 
are of emerging interest, particularly those at or just beneath the plasma 
membrane. The following subsections examine signals that functionally engage 
GLUT4 exocytosis, consider cytoskeletal regulation of the stimulated GLUT4 
itinerary, and appraise involvement of plasma membrane parameters in GLUT4 
control. Explored further are how these newly defined signaling, cytoskeletal, and 
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membrane mechanisms may be of therapeutic interest in the treatment and/or 
prevention of GLUT4 dysregulation in disease. 
 
 I.B.1. Recruiting GLUT4 
 Under normal insulin responsiveness, insulin promotes the removal of excess 
glucose from the circulation by stimulating the exocytic recruitment of intracellular 
GLUT4 storage vesicles (GSVs) to the plasma membrane (PM) of skeletal 
muscle and fat cells (25, 27). This stimulated redistribution of intracellular GSVs 
results in PM GLUT4 accrual that facilitates cellular glucose uptake (Fig. 1). 
Activation of GSVs by insulin requires a phosphatidylinositol 3-kinase (PI3K) 
signal involving the upstream insulin receptor (IR) and insulin receptor substrate 
(IRS) activators and the downstream Akt2 target enzyme (25, 27, 33). 
 Until the discovery of AS160 (Akt substrate of 160-kilodaltons (kDa)) in 2002 
(34), how the IR/IRS1/PI3K/Akt2 signal coupled to GSVs remained unclear. This 
protein, also known as TBC1D4 (Tre-2 BUB2 CDC16, 1 domain family member 
4), contains a GTPase activating domain (GAP) for Rabs, small G proteins 
implicated in vesicle trafficking (35, 36). In the basal state, the Rab-GAP function 
of TBC1D4 is thought to contribute to the intracellular retention of GSVs by 
promoting the inactive GDP-bound state of Rabs; whereas insulin-stimulated 
Akt2 suppresses the Rab-GAP activity of the TBC1D4 and thus increases the 
active GTP-bound form of Rabs on GSVs to promote exocytosis (Fig. 1A). 
Consistent with this localized functionality, TBC1D4 associates with GSVs via 
binding to the insulin-responsive amino peptidase (IRAP), a GSV cargo
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Figure 1. Schematic illustration of putative signals, cytoskeletal 
mechanisms, and plasma membrane parameters involved in insulin-
stimulated GLUT4 storage vesicle exocytosis (17).  
(A) Activation of GSVs by insulin requires a PI3K signal involving the upstream 
IR and IRS activators and the downstream Akt2 target enzyme. TBC1D4 and 
TBC1D1, substrates of Akt2, have been suggested to couple the PI3K/Akt2 
signal to GSVs via its action on one or more critical Rab proteins. The basal 
intracellular pool of GDP-Rab GSVs shown associated with several putative 
anchoring systems (e.g., microtubules, Ubc9 (ubiquitin-conjugating enzyme 9), 
TUG (tether containing UBX domain for GLUT4)) are activated by the 
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suppression of the Rab-GAP activity of TBC1D4/TBC1D1 by Akt2. Several 
putative Rab proteins, the existence of possible calcium regulation, and 
mechanisms associating TBC1D4 (and presumably TBC1D1) to the GSV via 
IRAP have been suggested (see inset). (B) Cortical F-actin, likely originating at 
the neck region of caveolae PM microdomains, plays a critical role in GSV 
trafficking. Reorganization of the cortical F-actin meshwork by insulin signaling to 
TC10 allows GSV/PM arrival, tethering, and docking. A large number of 
proposed insulin-regulated processes occur in this PM vicinity such as TC10-
regulated formation of the exocyst complex and cortical F-actin remodeling, 
PI3K/RalA-stimulated transition of trafficking GSVs to tethered GSVs, a role of 
ACTN4 and/or the exocyst complex in tethering, and an α-fodrin-mediated 
rearrangement of cortical actin filaments in the area of syntaxin 4 to facilitate 
GSV/PM SNARE protein interaction and docking (see inset). (C) Insulin 
signaling, through two putative PI3K signals that activate PKCδ/λ and PLD1, 
prepares GSVs for fusion with the PM. The first PKCδ/λ signal has been 
implicated in promoting the dissociation of Munc18c from syntaxin4, contributing 
to the fusion-competent SNARE complex. The second PLD1 signal primes the 
GSV and PM for fusion by generating PA, which has been suggested to act as a 
fusogenic lipid in biophysical modeling studies by lowering the activation energy 
for membrane bending (i.e., negative membrane curvature) during generation 
and expansion of fusion pores (see inset). 
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protein (37, 38). Another Rab-GAP known as TBC1D1 with identical Rab 
specificity as TBC1D4 (39) also displays similar regulation of GLUT4 in 3T3-L1 
adipocytes (39), skeletal muscle myotubes (40), and mouse skeletal muscle (41). 
Interestingly, expression of a TBC1D1 genetic variant (R125W, linked with 
human obesity (42)), was found to impair insulin-stimulated glucose transport in 
mouse skeletal muscle (41). However, studies of TBC1D1 function in 3T3-L1 
adipocytes showing that expression of wild-type TBC1D1 displays a similar 
inhibitory effect as R125W, and that GLUT4 regulation is intact following TBC1D1 
knockdown, raises questions on the importance of TBC1D1 and R125W in health 
and disease (40), (43). Nevertheless, given the high expression levels of 
TBC1D1 in skeletal muscle compared to adipocytes (43), future attention on 
TBC1D1 functionality in GLUT4 regulation has merit. Another important area of 
current investigation is aimed at identifying which Rab protein(s) are targeted by 
TBC1D4 and TBC1D1 Rab-GAP activity (Fig. 1A, inset). 
Using immunoblotting and mass spectrometry techniques to analyze GLUT4-
containing intracellular vesicles, the Rab proteins Rabs 4, 5, and 11 have been 
shown to associate with GSVs (35, 36). Additional evidence from proteomic 
analysis (44) and mass spectrometry (45) demonstrates that Rabs 2, 8, 10, and 
14 are associated with GSVs, raising questions as to which Rabs are important. 
Historically, Rab4 has been a major Rab of focus in GLUT4 regulation (36); 
however, new evidence suggests that other Rabs may play roles in regulating 
GLUT4. The highly homologous nature of Rab proteins, lack of antibodies 
specific for Rabs, and potential false positives represent ongoing challenges in 
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dissecting specific Rabs associated with GSVs in subcellular fractionation and 
immunlocalization studies (36). Moreover, establishing a functional significance 
for one or more Rabs in GSV trafficking has been challenging. Functionally, Rabs 
2, 8A, 10, and 14 have been identified as putative targets of TCB1D4 in vitro 
(45). Recent studies have utilized siRNA (small interfering RNA) knockdown of 
Rabs to more precisely dissect roles in GLUT4 regulation, as interpretation of 
data from overexpression-based analyses are complicated by potential off target 
effects on other Rabs and Rab effectors. Knockdown of Rab10 in adipocytes has 
suggested a role for Rab10 in insulin-stimulated GLUT4 translocation (46). These 
results are supported by findings showing that only knockdown of Rab10, not that 
of Rabs 8A, 8B, and 14, prevented insulin-stimulated GLUT4 translocation in 
3T3-L1 adipocytes (47). In line with earlier findings regarding Rab4 (36), Rab 4B 
knockdown in adipocytes supports its role in regulating GLUT4 translocation (48). 
In muscle cells the Rabs 8A and 14, but not Rabs 8B and 10, rescue the 
inhibition of GLUT4 translocation by a constitutively-active TBC1D4 (49). 
Consistent with these findings, knockdown of Rabs 8A and 14 inhibits insulin-
stimulated GLUT4 translocation (50) implicating these Rabs in muscle GLUT4 
regulation. Although Rab specificity is not completely dissected, together these 
studies begin to establish tissue-specific roles for Rab proteins in GLUT4 
translocation and highlight the crucial need for future efforts to fill this gap in our 
understanding. 
Although it was hoped that the discovery of TBC1D4 would lead to the 
precise identification of the GSV-regulatory Rab protein, the finding of TBC1D1 
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and several GSV-associated Rabs that are targeted by TBC1D4 and TBC1D1 
have provided additional advances in our understanding that will require further 
study. In this regard it is intriguing that calmodulin has been reported to bind to a 
small domain just amino terminal to the GAP domain of TBC1D4 (51). The 
association was calcium dependent. Nevertheless, study of a point mutant of 
TBC1D4 lacking calmodulin binding did not seem to indicate a requirement for 
calmodulin/TBC1D4 binding in GLUT4 regulation. Perhaps this calmodulin-
binding domain regulates contraction-, but not insulin-, stimulated GLUT4 
regulation (52). Despite these data fitting a calcium-independent model of insulin-
regulated GLUT4 translocation, intermittent study through the years seems to 
support a role of calcium (53). Interestingly, new studies have identified 
requirements for inositol 1,4,5-triphosphate-receptor and calcium/calmodulin-
dependent protein kinase II pathways in GLUT4 regulation by insulin (54, 55). 
These new insights support the need for future investigation into calcium-based 
aspects of GLUT4 control. 
In summary, new additions to our understanding of GSV recruitment have 
been made. Namely, data implicate that insulin-mediated suppression of the 
Rab-GAP activity of GSV-localized TBC1D4 (and presumably TBC1D1) activates 
a critical GSV-regulatory Rab protein. Although the precise identification of the 
Rab protein or proteins involved in GSV recruitment needs continued delineation, 
data from several studies have framed key cytoskeletal events distal to Rab 
functionality in the itinerary of the activated GSV. 
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I.B.2. Motoring GSVs 
Conceptually, a long-standing view has been that microtubules coordinate 
long-range, whereas actin orchestrates short-range, GSV movement (21, 56, 57). 
Findings implicate microtubules in mediating basal subcellular distribution of 
GSVs, but not the accelerated rate of GLUT4 translocation stimulated by insulin 
(58). For example, basally GSVs display long-range movements beneath the PM, 
with their trajectories extensively spread on the entire PM (59). This is consistent 
with findings that insulin stimulation halts this long-range GSV basal itinerary and 
stimulates GSV/PM tethering, docking, and fusion in rat primary adipocytes (60). 
Recent mounting evidence discussed below supports that this insulin-stimulated 
switch from a basal GSV trajectory to an insulin-regulated PM-bound track 
occurs at a microtubule/actin junction beneath the PM. 
It is well-documented that insulin elicits a rapid, dynamic remodeling of actin 
filaments into a cortical mesh, and this mesh is necessary for GLUT4 
translocation in both cultured and primary skeletal muscle and fat cells (21). At a 
functional level, new studies by several groups continue to point to important 
roles of several recognized and new insulin-regulated proteins (e.g., TC10 (61), 
actin-related proteins 2/3 (Arp2/3) and Cofilin (62), Myo1c (55), Rac1 (63), focal 
adhesion kinase (FAK) (64)) that control actin dynamics to influence GLUT4 
translocation, some of which we provide more detail on below. More relevant to 
the present discussion are data that place GSVs in the meshwork and suggest a 
functionality of the actin mesh in GLUT4 translocation (Fig. 1B). For example, 
alpha-actinin-4 (ACTN4), a protein responsible for linking actin filaments to 
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intracellular structures, is required for insulin-stimulated GLUT4 translocation in 
L6 myotubes (65). Mechanistically, ACTN4 co-precipitated and co-localized with 
GLUT4 along actin filaments induced by insulin stimulation, suggesting that 
ACTN4 may play a role in tethering GSVs to the actin cytoskeleton (Fig. 1B, 
inset). The tethering function of the cortical actin mesh likely plays a critical role 
in the final steps of GSV/PM docking and fusion regulated by syntaxin 4 and 
synaptosomal-associated protein 23 (SNAP23) target (t-) soluble N-
ethylmaleimide sensitive factor attachment protein receptors (SNAREs) and the 
GSV vesicle (v-) SNARE vesicle-associated membrane protein 2 (VAMP2) (66). 
Together these findings provide evidence that ACTN4 may direct GSVs to the 
insulin-organized cortical actin meshwork to facilitate GSV delivery to the 
appropriate PM-localized SNARE-mediated docking machinery. 
In cultured and primary adipocytes an evolutionarily conserved tethering 
complex termed the exocyst complex has been described for GSV/PM targeting 
(67, 68). This complex, comprised of eight subunits, mediates the initial 
recognition of the exocytic vesicle and target membranes for fusion. The 
assembly of the adipocyte GSV exocyst complex occurs at PM caveolae/raft 
regions and requires insulin activation of the Rho family member GTPase TC10, 
which mediates recruitment of exocyst components Exo70, Sec6, and Sec8 (67). 
Interestingly, activation of TC10 also appears necessary for the regulation of 
cortical filamentous actin (F-actin) reorganization (Fig. 1B, inset), which we 
discuss further below. Along with insulin activation of a Rab GTPase for GSV 
recruitment and a Rho GTPase for GSV/PM arrival, insulin also activates a GSV-
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associated Ral GTPase termed RalA that induces GSV/exocyst association 
juxtaposed to the PM (Fig. 1B, inset) (69). The observation that RalA interacts 
with Myo1c, a molecular motor implicated in GSV trafficking, implicates a 
convergence of vesicle trafficking to tethering (55, 69). 
 Of interest are the insulin signals to each of the GTPases. Similar to Rab 
activation, insulin signaling to RalA is PI3K-mediated (69). Whereas the 
PI3K/Rab signal involves Akt2 signaling to TBC1D4 and/or TBC1D1, it remains 
unclear if PI3K signaling to RalA involves Akt2 stimulation and distal signaling to 
TBC1D4, TBC1D1, or a yet to be determined substrate. Unlike Rab and RalA 
activation, insulin is appreciated to use a PI3K-independent signal to activate the 
Rho GTPase TC10. Although initial study delineated several component proteins 
(e.g. APS (adaptor protein containing PH and SH domains), c-Cbl, CAP (Cbl-
associated protein), CrkII/C3G) involved in this TC10 activation, subsequent 
siRNA knockdown studies challenged their proximal importance in TC10-
regulated GLUT4 translocation (70). Subsequent study revealed that TC10 has 
two isoforms (TC10α and TC10β), and that insulin-stimulated TC10α, not TC10β, 
regulates GLUT4 translocation (61, 71). With the use of pharmacological 
inhibitors and siRNA-mediated knockdown, study has delineated that proximal 
insulin signaling to TC10α-, but not TC10β-, involves the activation of cyclin-
dependent kinase-5 (CDK5) in caveolae/raft domains via proximal non-receptor 
tyrosine kinase Fyn activation by insulin (71). Furthermore, this work shows that 
active CDK5 maintains TC10α in caveolae/rafts where it functions to disrupt 
cortical F-actin. 
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With regards to actin, identification of α- and β-fodrin isoforms as abundant 
components of rat primary adipocyte PM caveolae/rafts is of interest (72). Fodrin 
is a nonerythroid spectrin that forms filamentous α-β heterodimers and binds to 
actin at both ends, forming a repeating “corral”-like network beneath the PM. 
Interestingly, α-fodrin and syntaxin 4 co-localize and interact in rat adipocytes, 
and insulin enhances this interaction. In contrast, disruption of cortical actin by 
latrunculin A reduces the α-fodrin-syntaxin 4 interaction, blocks α-fodrin 
remodeling, and inhibits GLUT4 translocation. In this case, the regulated 
remodeling of the fodrin-actin network apparently plays a key role in permitting 
GSV/PM fusion by allowing GSV-VAMP2 access to syntaxin 4 (Fig. 1B, inset). 
Once insulin-stimulated α-fodrin remodeling had occurred GLUT4 translocation 
became insensitive to latrunculin A, suggesting that only the exocytic step of 
GLUT4 translocation at or near the PM requires this aspect of cortical F-actin 
remodeling (72). 
In summary, these data are consistent with the concept that the insulin-
stimulated motoring of the GSV, subsequent to its Rab recruitment signal, 
requires insulin signaling to RalA by an undefined PI3K mechanism and to 
TC10α via a Fyn/CDK5 pathway. Whereas RalA activation stimulates the 
trafficking GSV to tether with the caveolae/raft-localized exocyst complex, active 
TC10α regulates the formation of the exocyst complex for GSV tethering and 
also reorganizes the cortical F-actin for GSV docking. Together these studies 
may suggest that the exocyst-tethered GSV transitions to a syntaxin 4/SNAP23-
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docked GSV by the possibility that fodrin couples syntaxin 4 to caveolae-
localized F-actin, in which data presented below seem to support. 
 
 I.B.3. Bilayering GSVs 
It is clear that the regulated meshwork of actin filaments beneath the PM 
plays a critical role in several steps of the GSV itinerary, particularly GSV arrival, 
tethering, and docking. In addition to a likely role of bilayer parameters in GSV 
recruitment and mobilization steps, new data indicate that insulin-regulated 
changes in PM lipids promote GSV/PM fusion. As lipids are key 
pathophysiological players in disorders of glucose metabolism, studies 
demonstrating an impact of PM lipids on insulin action and GLUT4 translocation 
warrant consideration. The next section describes data from several microscopy-
based explorations of PM functionality that provide new insight into PM/F-actin 
coupling and GSV/PM fusion regulation by insulin. 
Caveolae represent specialized, morphologically distinct sphingolipid-
cholesterol microdomains of the PM, which are stabilized by caveolin proteins 
(73). Through the years many functions for caveolae have been postulated in 
insulin and GLUT4 action. Although caveolae functionality needs to be cautiously 
interpreted because problems are associated with each of the numerous 
strategic approaches used to study these structures, a caveolae-based 
TC10α/exocyst complex tethering and cortical F-actin dispersion mechanism in 
this vicinity is consistent with data implicating a caveolae-actin association (74, 
75). Particularly, fluorescence confocal labeling of caveolae and cortical F-actin 
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revealed actin filaments emanating from caveolae microdomains (74). Whereas 
disruption of this caveolin-associated F-actin, termed Cav-actin, structure with 
latrunculin B, Clostridium difficile toxin B or a dominant-interfering TC10 mutant 
(TC10/T31N) did not affect the organization of clustered caveolae; disruption of 
the clustered caveolae with methyl-beta-cyclodextrin (β-CD) dispersed the Cav-
actin structure (74). Quantitative electron microscopy and freeze-fracture 
analyses later revealed that cytoskeletal components, including actin, are highly 
enriched in the membrane area underlying the neck part of caveolae (75). 
Together, these findings assign caveolae with a critical functionality in cortical F-
actin organization. Given the unequivocal importance of cortical F-actin in insulin-
regulated GLUT4 translocation, these findings also emphasize the importance of 
caveolae in GLUT4 regulation. Of interest to our understanding of Cav-actin 
structure regulation are new electron microscopic data that show 
phosphatidylinositol 4,5 bisphosphate (PIP2) is highly concentrated at the rim of 
caveolae (76). This localization of PIP2 is consistent with its regulation of the 
cytoskeleton where this lipid’s availability is recognized to modulate 
membrane/cytoskeleton interaction, the stability of cortical F-actin, and the 
turnover of cytoplasmic stress fibers (77). Interestingly, reduced PM PIP2 and 
cortical F-actin structure are observed in hyperinsulinemia-induced insulin-
resistant 3T3-L1 adipocytes and L6 myotubes where insulin-stimulated GLUT4 
translocation is impaired, but corrected with exogenous PIP2 addition to the PM 
by provoking a restoration of cortical F-actin structure (7, 78). 
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Given the emerging evidence of PM functionality in GLUT4 regulation, several 
recent studies have employed total internal reflection microscopy (TIRFM) to 
critically examine GSV/GLUT4 regulation. This microscopy uses an evanescent 
wave to selectively illuminate and excite fluorophores in a restricted region of the 
cell immediately adjacent to the PM. This further experimental scrutiny has 
expanded upon findings from cell-free reconstitution assays showing insulin 
activation of the PM fraction of the in vitro reaction is the essential step in 
GSV/PM fusion (79). For example, several TIRFM analyses have provided strong 
evidence for a critical PM signal that appears to prime the PM and/or the GSVs 
for fusion (80-82). With a combination of live cell and steady-state TIRFM 
analyses with PI3K and Akt inhibition, Akt was suggested to be a crucial 
regulator of insulin-stimulated GSV/PM pre-fusion (i.e., recruitment, tethering, 
docking) events (80). In contrast, insulin-stimulated GSV/PM fusion seemed to 
occur independently of Akt activity. That is, although GSV/PM prefusion was 
inefficient with Akt blockade, fusion of this lower level of docked GSVs with the 
PM was properly stimulated by insulin. However, based on inhibition of this 
GSV/PM fusion with wortmannin, it appears this postdocking step is PI3K 
dependent. Dynamic tracking of single GSVs with computational analysis of 
thousands of events lends strong support to this model whereby insulin uses a 
PI3K/Akt signal to accelerate GSV/PM prefusion and another signal to prepare 
GSVs and/or the PM for GSV/PM fusion (81). Although the steady-state analysis 
suggested this second signal required PI3K, this conclusion could not be made 
with live cell GSV tracking (80, 81). 
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Certainly, the putative role of PI3K in priming GSV/PM fusion requires 
confirmation, yet is of great interest as PI3K signaling to PKCδ/λ/Munc18c (83, 
84) and/or PLD1 (phospholipase D1) (85) could promote GSV/PM fusion (Fig. 
1C, inset). Whereas insulin signaling through PKCδ/λ has been proposed to 
dissociate Munc18c from syntaxin 4, a necessary postdocking/prefusion event 
(83, 84); PLD1 activation by insulin has been implicated in generating fusion-
competent membranes (86). Mechanistically, PLD1 generates the lipid 
phosphatidic acid (PA), which has been suggested to act as a fusogenic lipid in 
biophysical modeling studies by lowering the activation energy for membrane 
bending (i.e., negative membrane curvature) during generation and expansion of 
fusion pores (Fig. 1C, inset) (87). Together these data suggest PI3K may use 
two distinct signals to regulate critical mechanisms of GSV/PM fusion post 
GSV/PM docking. 
 
 I.C. Obesity, Insulin Resistance and GLUT4 Dysregulation 
New additions to the molecular details of GLUT4 regulation by insulin attest to 
the great progress being made in our mechanistic understanding of insulin-
stimulated glucose transport in health and disease. As highlighted earlier, the 
prevalence of diabetes in the United States continues to rise, but more troubling 
is the escalating global impact of this disease. Despite the increase in 
knowledge, global prevalence of diabetes in 2010 was 284 million people 
worldwide, constituting around 6.4% of the world population. Projections for 2030 
estimate the prevalence reaching 439 million individuals, comprising ~7.7% of 
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the world population (88). This is attributed in large part to the rising incidence of 
obesity worldwide, which makes it essential to focus attention on molecular 
mechanisms underlying insulin resistance that are fueled by obesity. Insulin 
resistance is a complex, progressive syndrome with many associated 
pathologies. Extensive research efforts are underway to continue unraveling 
these complex mechanisms linking nutrient oversupply to insulin resistance. The 
subsections below will outline fundamental findings that have uncovered various 
mechanisms underlying the complex nature of insulin resistance in skeletal 
muscle.  
 
I.C.1. Lipid-induced insulin resistance 
In the context of abundant nutrient supply and lack of physical activity in the 
developed world, it has become apparent that excess FAs have a negative effect 
on skeletal muscle insulin sensitivity. Insulin resistance is highly correlated with 
obesity (89, 90), increased circulating FAs and the accumulation of lipids in 
skeletal muscle and adipose tissue (91, 92). Outlined below are several 
proposed mechanisms that begin to explain the role FA’s play in the 
development of insulin resistance (93).  
 Numerous hypotheses have been proposed throughout the years in an effort 
to explain how FAs and their metabolites directly induce insulin resistance. The 
first major hypothesis linking FAs to glucose metabolism was proposed by 
Randle and colleagues. The Randle hypothesis suggested that FAs directly 
compete with glucose for the same oxidative pathway, which impairs glucose 
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metabolism in the face of increased FAs (94). More recent studies have 
disproven this early hypothesis. Using 13C and 31P nuclear magnetic resonance 
(NMR) spectroscopy to analyze insulin-resistant humans, it has been shown that 
the major defect underlying insulin resistance is glucose uptake (95) and 
glycogen synthesis (96) in skeletal muscle, rather than impairment in glucose 
catabolism (97). In further support of defective glucose uptake accounting for 
insulin resistance, lipid infusion has been shown to impair tyrosine 
phosphorylation of IRS. Lipid infusion also increases activation of PKCθ, which is 
a Ser/Thr kinase which is also expressed higher in HF-fed rats compared to low 
fat (LF)-fed rats (98). Based on these observations, Shulman and colleagues 
hypothesized that serine phosphorylation of IRS is the primary mechanism 
involved in FA-induced insulin resistance (99). This model implicates FAs and 
their metabolic intermediates (i.e. acyl-Co enzyme A (CoA)s, ceramides and 
diacylglycerides (DAGs)) as signaling molecules. These signaling lipids can 
phosphorylate serine residues of IRS, which causes defects in tyrosine 
phosphorylation of IRS and disrupts downstream insulin signaling (95, 99). 
 A related hypothesis has been proposed by Summers and colleagues based 
on the observation that saturated FAs have a more deleterious effect on insulin 
sensitivity compared to unsaturated FAs (100). This model was supported by the 
observation that palmitate, the most prevalent saturated FA in the circulation and 
skeletal muscle (101), stimulates de novo synthesis of ceramide. The 
sphingolipid ceramide has a potent negative effect on insulin signaling at the 
level of Akt phosphorylation (6, 9, 102). In further support of this mechanism, 
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ceramide levels are negatively correlated with insulin sensitivity in humans (103). 
When cultured skeletal muscle cells and adipocytes are treated with ceramide 
analogues in vitro, these cells become insulin-resistant, as evidenced by findings 
from several independent studies showing defects in insulin-stimulated glucose 
uptake and glycogen synthesis (6, 9, 104, 105). Palmitate-induced defects in Akt 
phosphorylation in cultured C2C12 myotubes and human myotubes are 
prevented by treatment with inhibitors of ceramide synthesis (6, 106-108). 
Moreover, depletion of ceramide pools by overexpressing acid ceramidase also 
confers protection against palmitate-induced defects in Akt activation (109). The 
mechanisms by which ceramide inhibits insulin signaling at the level of Akt 
phosphorylation appear to involve the protein phosphatase 2A (PP2A), inhibition 
of Akt translocation to the PM and activation of Ser/Thr kinases including JNK 
and IKK. PP2A was identified as a target for ceramide-induced insulin resistance 
(110), as PP2A has been shown to dephosphorylate Akt and reduce insulin 
signaling resulting in insulin resistance (111). In addition, ceramides have been 
shown to prevent the translocation event of Akt to the PM to allow Akt 
phosphorylation and activation. The prevention of Akt translocation has been 
shown to be mediated by PKCδ phosphorylating Akt on its PH domain at Ser34 
(112). This phosphorylation event prevents the binding of Akt with 
phosphatidylinositol 3,4,5 triphosphate (PIP3) at the PM (112). These findings are 
supported by the observations that PKCδ inhibitors and expression of a dominant 
negative form of PKC prevents the negative effects of ceramide on insulin 
sensitivity (106). Finally, ceramides have also been shown to induce insulin 
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resistance by activating Ser/Thr kinases such as JNK and IKK mediated by the 
inflammatory cytokine tumor necrosis factor alpha (TNFα) (113-115). 
 It is well appreciated that chronic, systemic inflammation is associated with 
insulin resistance. There are a multitude of effects of the inflammatory state 
associated with obesity, not just including ceramide-associated defects, which 
are implicated in the development of insulin resistance (116-118). Systemic 
inflammation is known to result in macrophage accumulation in adipose tissue 
(119, 120) and more recently skeletal muscle (121), for example. The expanding 
fat mass in obesity leads to an activation of these macrophages that stimulate 
the production of inflammatory cytokines such as TNFα, C-reactive protein (CRP) 
and interleukin-6 (IL-6). These inflammatory cytokines wreak havoc on insulin 
signaling by activating JNK in skeletal muscle, leading to increased serine 
phosphorylation of IRS and insulin resistance (95, 99). Cytokines are also 
associated with activation of SOCS proteins (122, 123), which decrease IRS 
tyrosine phosphorylation and target IRS for proteasomal degradation (124, 125). 
Although the mechanisms will not be discussed in detail, mitochondrial 
dysfunction is another important aspect of insulin resistance of emerging interest. 
Defects in mitochondria are known to increase oxidative stress and production of 
reactive oxygen species that negatively impact insulin sensitivity (126, 127). The 
mechanisms described in this section likely contribute to insulin resistance 
interdependently, as insulin resistance is well accepted to be a complex interplay 
of many different factors (93). While lipid-induced mechanisms have been shown 
to involve signaling defects leading to insulin resistance, several groups have 
25 
 
also identified states of insulin resistance induced by excess insulin and glucose 
exposure, for example, that do not involve defects in key insulin signaling 
proteins. The emerging appreciation of these complementary aspects of GLUT4 
regulation and insulin sensitivity will be described in the following subsections.    
 
I.C.2. Insulin- and glucose-induced insulin resistance  
Similarly to FAs, increased levels of insulin and glucose have been shown to 
negatively impact insulin sensitivity in both in vitro and in vivo experimental 
models (4-15). The pathophysiology of insulin resistance involves a 
compensatory increase in insulin secretion by the β-cells to account for reduced 
insulin sensitivity in skeletal muscle. Although hyperinsulinemia is typically 
viewed as a compensatory response by the pancreas to offset insulin resistance, 
studies in man (128, 129) and in cultured cells (130, 131) have clearly shown that 
insulin resistance can be induced by hyperinsulinemia. These data, coupled with 
the fact that it is difficult to find a study in which insulin resistance and 
hyperinsulinemia are clearly separated in time (132), suggest a scenario where 
hyperinsulinemia may actually cause insulin resistance. Regardless of the exact 
temporal sequence in which these derangements appear, hyperinsulinemia is 
widely viewed to accelerate diabetes progression and worsen prognosis (132, 
133). In fact, plasma insulin has been measured in multiple population-based 
studies which demonstrate an important clinical impact of hyperinsulinemia (134). 
For example, obesity, impaired glucose tolerance, T2D, hypertension and 
hypertriglyceridemia were found to be two to three times more prevalent in 
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individuals with fasting insulin levels of greater than 31 µU/ml (186 pm) than in 
subjects with fasting insulin below that level. Cell studies testing the effects of 
chronic insulin exposure have documented attenuated expression levels and/or 
activity states of insulin signaling intermediates. However, these studies used 
concentrations of insulin >16,666 µU/ml (100 nM), concentrations ~500-fold 
greater than the 31 µU/ml-defined hyperinsulinemic cutoff. Several groups (14, 
15), including ours (7, 8), show that 12-18 hour exposure of cells to more 
physiologically relevant insulin concentrations [100-833 µU/ml; 600-5000 pM] 
(134) induces insulin resistance while proximal insulin signaling remains intact. 
Similarly to hyperinsulinemia, exposure of muscle and fat cells to excess 
glucose has also been shown to negatively impact insulin sensitivity. The fuel 
sensing pathways involved in chronic overnutrition are not well understood and 
likely very complex. An emerging appreciation in the context of excess nutrients 
and obesity contributing to insulin resistance is the involvement of the 
hexosamine biosynthesis pathway (HBP) in regulating glucose flux. The HBP is 
considered as a nutrient sensor, as HBP flux parallels glucose availability (135, 
136). Under normal nutrient load, 2-5% of glucose that enters the cells is shunted 
from the glycolytic pathway to the HBP (137, 138). HBP flux is regulated by the 
pathway’s rate limiting enzyme, glutamine:fructose-6-phosphate 
amidotransferase (GFAT) (139). Flux through the HBP ultimately results in 
conversion of substrate to uridine diphosphate-N-acetylglucosamine (UDP-
GlcNAc). Single GlcNAc moieties are transferred to hydroxyl groups on Ser/Thr 
residues of target proteins by O-linked N-acetylglucosamine transferase (OGT) 
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(140). Removal of the O-GlcNAc moiety is achieved by the enzyme O-
GlcNAcase (OGA) (141, 142). Therefore, the rapid and transient cycling of this 
post translational modification is a rapid and transient nutrient-sensing signaling 
mechanism. O-GlcNAc has been implicated in cellular processes such as 
transcriptional regulation, signal transduction and metabolism (143, 144). These 
O-GlcNAc modifications are common for both cytoplasmic and nuclear proteins 
(142, 145). While the HBP pathway and its regulation is not the major focus of 
my thesis research, the relevant implications of increased HBP flux and impact 
on membrane/cytoskeletal parameters of insulin sensitivity will be described in 
further detail below.  
 The nutrient-sensing HBP is a classical example of a normal evolutionary 
adaptation; however, chronic HBP flux has been shown to induce defects 
associated with the pathophysiology of insulin resistance. Marshall and 
colleagues first described the detrimental effects of excess HBP flux (138). This 
study showed that exposure of cultured adipocytes with hyperglycemia induced 
an insulin-resistant phenotype (138). This hyperglycemia-induced insulin 
resistance has been shown to involve defects in GLUT4 translocation and 
glucose transport (146, 147). Studies have shown that the effects of 
hyperglycemia and glucosamine treatments used to drive the HBP pathway are 
not additive, suggesting a shared pathway (148). In vivo studies have also 
implicated the HBP in the development of insulin resistance. For example, 
overexpression of GFAT has been shown to result in insulin resistance (135, 
149-151). In addition, inhibition of OGA increases O-GlcNAc levels and induces 
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insulin resistance (152). Although elevated levels of O-GlcNAc are also 
associated with insulin resistance in a variety of cell types (151, 152), the 
mechanisms by which increased HBP flux induces insulin resistance are not 
completely understood. Recent findings have suggested that OGT is targeted to 
the PM by phosphoinositides where OGT increases O-GlcNAcylation and inhibits 
key insulin signaling proteins (153). Alternative studies have suggested that O-
GlcNAcylation competes with phosphorylation on Ser/Thr residues to impact 
cellular signaling events (154). 
    Published data, as well as new unpublished data, from our group have 
demonstrated that HBP flux through palmitate, hyperglycemia and glucosamine 
treatments promotes key transcription factors that induce membrane cholesterol 
accrual and F-actin defects associated with cellular insulin resistance (10, 11, 23, 
24). To further support a mechanism of HBP flux inducing insulin resistance, 
palmitate-, hyperglycemia- and glucosamine-induced membrane/cytoskeletal 
defects and insulin resistance were prevented by HBP inhibition (10, 11, 24). Our 
results suggest that compensatory hyperinsulinemia is likely to increase glucose 
flux even in euglycemic conditions, highlighting an important aspect of pre-
diabetes that may be prevented by modulating the HBP. In addition to its roles as 
a sensor of glucose load, HBP flux is also likely influenced by excess lipids (10, 
137). The HBP is emerging as a key fuel sensing pathway in the regulation of 
cellular cholesterol accrual. A possibility we favor involves increased HBP flux 
resulting in a transcriptional reprogramming of the cell to a more cholesterogenic 
phenotype (10, 11, 23). To further describe the involvement of cholesterol in 
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insulin resistance, the following subsection will briefly describe how cellular 
cholesterol levels are regulated and how cellular cholesterol becomes 
dysregulated in the development of insulin resistance. 
 
I.C.3. Cholesterol dysregulation in insulin resistance 
A role for cholesterol in the pathogenesis of cardiovascular disease is well 
recognized (155). Furthermore, an appreciation is emerging for the role of 
cholesterol in glucose homeostasis and development of metabolic and 
neurodegenerative diseases (156-158). Cholesterol regulation is a very tightly-
regulated process. However, increased cellular, and specifically membrane, 
cholesterol levels are implicated in provoking insulin resistance. Cellular 
membranes are composed of cholesterol and phospholipids, and these lipids are 
essential for membrane structure and function (159-161). Cholesterol 
organization in the membrane is complexly regulated and depends on both 
cholesterol concentration and membrane composition (162, 163). Cholesterol 
has been shown to have preferential interactions with particular membrane lipids 
and proteins to form microdomains, known as lipid rafts, essential for cell 
function, signaling, adhesion and motility (73, 164-166). The majority of cellular 
cholesterol (65-90%) is found in the PM (159) as opposed to intracellular 
membranes, and cholesterol comprises 35-45% of all PM lipid species (167). 
Low density lipoprotein (LDL) delivers extracellular cholesterol to cells; however, 
all nucleated cells can synthesize cholesterol de novo. The cholesterol 
biosynthesis pathway utilizes acetyl CoA to convert mevalonate to lanosterol, 
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which is eventually modified to form cholesterol by several downstream 
enzymatic reactions (168). 
Cholesterol is essential for cellular structure and function; however, it can also 
have detrimental effects. Therefore, cholesterol regulation is complexly controlled 
to maintain a balance between synthesized cholesterol and external cholesterol 
delivered by LDL. Cholesterol regulation is primarily regulated by a feedback 
mechanism to control 3-hydroxy-3-methyl-glutaryl coenzyme A reductase 
(HMGR) protein levels. HMGR is the rate limiting enzyme of cholesterol 
synthesis (169). Protein levels of HMGR are regulated by the sterol response 
element binding protein (SREBP) 2, SREBP cleavage-activating protein (SCAP) 
and insulin-induced protein (INSIG) 1 and 2 (170). An extremely small portion of 
cellular cholesterol (0.5%) is contained in the endoplasmic reticulum (ER) 
membrane and functions as a major regulatory mechanism (171, 172).  
The continued rapid exchange of cholesterol between the ER and PM allows 
the cell to monitor cellular and membrane cholesterol levels (160, 173, 174). 
Specifically, in a state of sufficient sterol levels (>5% of total ER lipids), HMGR 
and SCAP bind to INSIG (175). HMGR is ubiquitinated and degraded following 
binding to INSIG, while SCAP and the bound SREBP are retained in the ER 
(176, 177). Because SREBP-2 is a transcription factor responsible for activation 
of transcription of all cholesterogenic genes (178, 179), this retention of SREBP-
2 prevents further sterol synthesis to maintain cellular sterol homeostasis. 
However, when sterol levels drop below 5% of total ER lipids, HMGR and SCAP 
no longer bind INSIGs (175). The release of HMGR and SCAP prevents HMGR 
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degradation and promotes the trafficking of SCAP/SREBP from the ER to the 
Golgi complex to form the mature forms of the SREBP transcription factors that 
translocate to the nucleus (170, 180, 181). Mature SREBPs bind to the sterol 
response element (SRE) in the nucleus and activate genes necessary for sterol 
synthesis (178, 179), including up to a 200-fold increase in HMGR transcription 
(182, 183). It is of interest that the expression of specific SREBP isoforms, 
including SREBP-1c, is enhanced by insulin in liver, fat and skeletal muscle (184-
187). In addition, hyperinsulinemia has been shown to increase SREBP-1 
expression (188-190), which is responsible for regulating genes involved in fatty 
acid synthesis and to a lesser extent genes involved in cholesterol synthesis 
(178). Expression of SREBP-2, on the other hand, is mainly regulated by cellular 
cholesterol levels (191). 
Another aspect of cholesterol regulation involves phosphorylation events 
targeting enzymes in the cholesterol synthesis pathway (192). For example, 
HMGR activity is regulated by phosphorylation, and insulin exposure has been 
specifically shown to increase HMGR activity (192). As described in detail below, 
the cellular energy sensor AMPK phosphorylates HMGR to regulate cholesterol 
levels depending on cellular energy status (193, 194). HMGR is also regulated by 
the cholesterol synthesis pathway itself by a feedback inhibition loop by which a 
downstream intermediate of cholesterol synthesis, lanosterol, can target HMGR 
for proteasomal degradation to decrease cholesterol levels (195). Another 
mechanism by which cells decrease cholesterol levels is through Acyl-coenzyme 
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A:cholesterol acyltransferase (ACAT) mediated esterification and storage of 
cholesterol (196).  
Trafficking events involving the ATP-binding cassette transport proteins 
(ABCA1 and ABCG1) mediate efflux of cholesterol from cells (197, 198). The 
nuclear factor liver X receptor (LXR) facilitates cellular cholesterol efflux by 
binding in heterodimers to the retinoic X receptor (RXR) (199). LXR becomes 
activated by ligand binding, which has been suggested to involve oxysterols or 
intermediates from the steroid hormone and cholesterol synthesis pathways 
(200, 201). When ligands bind LXR, this nuclear factor binds to target promoters 
such as ABCA1 to induce gene transcription and promote cellular cholesterol 
efflux (202). As described above, the balance of cholesterol synthesis and efflux 
tightly regulates cellular cholesterol levels. However, studies suggest that 
cholesterol can become dysregulated and contribute to cellular insulin resistance.  
Insulin resistance and the metabolic syndrome are closely associated with 
dyslipidemia, and specifically alterations in circulating and cellular cholesterol 
levels. Specifically, insulin resistance is associated with elevated LDL and 
decreased high density lipoprotein (HDL) levels. These alterations suggest that 
insulin resistance is closely related to dysregulation of cholesterol homeostasis 
(203). As previously described, insulin enhances expression of SREBP-1c (184-
187). Furthermore, hyperinsulinemia has been shown to increase SREBP activity 
(188-190), and presumably cholesterol synthesis machinery. Along with SREBP-
1c, insulin has also been shown to enhance HMGR activity (192). Of interest is 
recent evidence from our group demonstrating that hyperinsulinemia induces 
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membrane cholesterol accrual that impairs the trafficking of the cholesterol 
transporter ABCA1 and cholesterol efflux in 3T3-L1 adipocytes (24), potentially 
involving the HBP activation. Furthermore, our recent data highlights the role of 
membrane cholesterol accrual in the pathophysiology of insulin resistance (10, 
11, 23). New data demonstrate increased membrane cholesterol levels in 
skeletal muscles membranes obtained from insulin-resistant mice, rats, swine 
and humans (10). Importantly, our analyses suggest an inverse relationship 
between membrane cholesterol content in human skeletal muscle biopsies and 
glucose disposal rate (10). It is now apparent that excess nutrient exposure in the 
forms of hyperinsulinemia, hyperglycemia and dyslipidemia can increase 
membrane cholesterol content and perturb GLUT4 regulatory components 
leading to insulin resistance. However, it remains unclear if skeletal muscle 
membrane cholesterol accrual contributes to cytoskeletal-based defects 
associated with hyperinsulinemia-induced insulin resistance and whether 
membrane/cytoskeletal defects can be therapeutically reversed by Cr3+ and 
AMPK action. Based on the fundamental concepts implicating cholesterol 
dysregulation and insulin resistance, the following subsection will specifically 
consider membrane/cytoskeletal derangements that impair GLUT4 regulation by 
insulin. 
 
I.C.4. Membrane/cytoskeletal derangements in insulin resistance 
Of particular interest to our group are the PM lipid environment and cortical 
actin cytoskeleton, which are required for the tethering, docking and fusion of 
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GSVs with the PM upon insulin stimulation. Based on evidence from multiple 
groups, it is well known that cortical F-actin dynamics are essential for insulin-
regulated glucose transport in skeletal muscle and adipose tissue (72, 204-211). 
The cortical F-actin cytoskeleton, located immediately beneath the PM, is a 
highly-dynamic meshwork. The proximity of the cortical F-actin meshwork with 
the PM suggests an interplay between the PM and regulation of actin remodeling 
required for GLUT4 translocation (18, 21, 205-207, 212, 213). Pharmacological 
disruption of the actin cytoskeleton with latrunculin (208, 214, 215), cytochalasin 
D (207) and botulinum toxin C2 (216) inhibits insulin-stimulated GLUT4 
translocation to the PM, supporting a crucial role for actin integrity in insulin 
action. It is well documented that insulin induces a very rapid reorganization of 
the cortical F-actin cytoskeleton, as early as 20 seconds following insulin 
stimulation, into a meshwork that involves membrane ruffling (204, 217, 218). In 
addition, actin comet-tails have been observed in adipocytes and skeletal muscle 
cells following insulin stimulation (215, 219, 220). Multiple groups have clearly 
shown that cytoskeletal derangements occurring in insulin resistance can disturb 
GLUT4 trafficking (7, 8, 16, 18-20), as recently reviewed (17, 21, 221). Studies 
from our group demonstrated that skeletal muscle insulin sensitivity critically 
relies on F-actin integrity (8, 18). In addition, our group has demonstrated that 
exposure of 3T3-L1 adipocytes and L6 myotubes to a physiologically relevant 
dose of insulin induces a loss of cortical F-actin and insulin resistance without 
detectable insulin signaling abnormalities (7, 8).   
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Several studies showing GLUT4 dysregulation without apparent defects in 
proximal insulin signaling point to the existence of other disabling factors of 
insulin-regulated GLUT4 exocytosis. With new signaling, cytoskeletal and bilayer 
additions available to our understanding, a major goal now is to precisely and 
accurately assess the functional status of the GLUT4 regulatory system. Whether 
critical flaws in cytoskeletal F-actin organization, lipid bilayer composition and/or 
GSV/PM fusion priming contribute to insulin resistance is not known, yet a clear 
association has been demonstrated between the diabetic milieu, cytoskeletal 
disorganization and bilayer abnormalities. For example, isolated neutrophils from 
patients with type 2 diabetes display decreased actin polymerization compared to 
neutrophils from non-diabetic control subjects (222). This impairment is 
associated with persistent expression of the endothelial adhering beta 2-integrin 
CD11b/CD18, potentially exacerbating vascular dysfunction in diabetic patients. 
Also, diabetic rat retinal endothelial cells have a prominent reduction in F-actin 
integrity, a finding closely linked to vascular leakage (223). Loss of rat mesangial 
cell F-actin has also been reported after exposure to early-diabetic state-like 
conditions (224), possibly causing diabetic hyperfiltration. Further support has 
been derived from examination of erythrocytes from overweight, insulin-resistant 
individuals which show marked changes in the phospholipid composition of the 
PM (225). 
With regards to insulin action and glucose transport, cholesterol complexing 
drug experiments have demonstrated that removal of cholesterol from the PM 
augments basal glucose uptake and metabolism (226, 227). Consistent with 
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cholesterol causing highly-ordered gel-like states, moderate increases in PM 
fluidity increase glucose transport in adipocytes (228). Consistent with membrane 
fluidity influencing GLUT4 regulation, insulin-stimulated glucose transport 
declines when fluidity diminishes (228). Mechanistically, it is now appreciated 
that non-physiological PM cholesterol depletion greater than 50% reduces the 
rate of internalization of PM GLUT4 by more than 85% (229). Although this 
certainly explains the gain in PM GLUT4, it is an artificial, experimentally-induced 
gain. In contrast, reductions of PM cholesterol less than 50% do not affect the 
rate of endocytosis, but do increase PM GLUT4 content (230). These later 
findings suggest moderate PM cholesterol lowering augments GSV exocytosis. 
In further support of a role for membrane cholesterol in regulating GSV 
exocytosis, several groups have demonstrated that hydrolysis of sphingomyelin 
by sphingomyelinase stimulates GLUT4 translocation to the PM and glucose 
transport (5, 230, 231). Our group further demonstrated that this insulin 
independent effect on GLUT4 and glucose transport was associated with a loss 
of PM cholesterol (230). Studies using methyl-β-cyclodextrin (βCD) (230), 
nystatin, filipin (230) and more recently Cr3+ treatment to lower membrane 
cholesterol have confirmed a key role of PM cholesterol in GLUT4 regulation (22, 
23). How these PM cholesterol-based aspects of GLUT4 regulation intermingle 
with insulin signaling and/or GSV regulation is unknown, yet coordinated 
signaling events and/or F-actin reorganization are areas of interest (21). Perhaps 
PM cholesterol toxicity contributes to impaired PIP2-regulated cortical F-actin 
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organization observed in insulin-induced insulin resistant 3T3-L1 adipocytes and 
L6 myotubes. 
Although speculative, we view this as a possible indication that 
membrane/cytoskeletal defects in skeletal muscle and/or adipose tissue could 
negatively impinge on GLUT4 translocation, perhaps before defects are induced 
in proximal insulin signaling. Supporting this view are studies using various cell 
model systems of insulin resistance that demonstrate insulin signaling to 
Akt2/TBC1D4 is not impaired (7, 13, 16, 19, 78, 232). Collectively these data 
point to the notion that some insulin-resistant states may result from a 
membrane/cytoskeletal-based mechanical defect in GSV/PM arrival, tethering, 
docking and/or fusion. In summary, several new essential features of insulin-
stimulated GLUT4 regulation have been revealed. From IR activation to GSV/PM 
fusion, multiple signals and a large number of processes apparently occur. 
Beyond GSV/PM fusion recent data also suggest that insulin continues to control 
the postfusion dispersal of GLUT4 in the PM (233). Although complete 
discussion of this new putative level of insulin regulation is out of the scope of 
this background, it exemplifies the fact that other unknown signals and processes 
likely await discovery. In the context of insulin resistance it becomes 
excruciatingly apparent why the failure of insulin-regulated glucose transport into 
skeletal muscle and adipose tissue is such an extremely difficult problem to 
solve. In conjunction with pinning down the complete mechanisms of the 
Akt2/GSV recruitment signal, the TC10/GSV tethering and actin reorganization 
system, and several putative PI3K transition signals (i.e., the RalA GSV 
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trafficking-to-tethering signal; the PKCδ/λ docking disassembly signal; and the 
PLD priming GSV/PM fusibility signal), important additional advances should 
include delineating the spatial and temporal aspects of all these signals and 
associated processes. Such additions will create a parallel opportunity to define 
the molecular events responsible for GLUT4 dysregulation in insulin resistance. 
 The studies described above have established membrane and cytoskeletal 
derangements as key distal aspects of insulin resistance that can impair insulin 
sensitivity independent of insulin signaling defects (7, 8, 10, 17-21). Interestingly, 
trivalent chromium (Cr3+) is a micronutrient that has been shown to have 
beneficial effects on glucose and lipid metabolism and has been suggested to 
impact membrane/cytoskeletal parameters of skeletal muscle insulin sensitivity; 
however, the cellular and molecular mechanism(s) of Cr3+ action are still not 
known. The following subsections consider the history of Cr3+ in health and 
disease, clinical benefits of Cr3+ supplementation and outline several proposed 
mechanisms for Cr3+ action in adipose tissue and skeletal muscle.  
 
 I.D. Chromium: History and Effects on Glucose/Lipid Metabolism 
The case for Cr3+ in the management of T2D began in 1957 with the 
discovery by Schwarz and Mertz that an unidentified substance in brewer’s yeast 
prevented the age-related decline of glucose tolerance in rats (234, 235). Two 
years later, Schwarz and Mertz identified this unknown “glucose tolerance factor” 
as chromium (234, 236, 237). Based on this identification, chromium was 
originally established as an essential nutrient in animals required for optimal 
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glucose and lipid metabolism (234), although this has recently been challenged 
(238). Regardless, humans are unable to produce Cr3+. Therefore, this nutrient 
must be obtained through dietary sources.  
In 1977, Cr3+  was declared an essential nutrient for humans when significant 
elevations in blood glucose, peripheral neuropathy and unexpected weight loss 
were first observed in a patient receiving total parenteral nutrition (239). This 
patient was found to be glucose intolerant as assessed by intravenous glucose 
tolerance test (IVGTT). Regular insulin and glucose infusions were effective at 
restoring normal body weight in this patient; however, the patient’s glucose 
intolerance was not improved. Levels of Cr3+ in the blood and hair were 
analyzed, and it was revealed that Cr3+ levels were extremely low compared to 
normally observed ranges. Based on the emerging roles of Cr3+ in glucose and 
lipid metabolism and the fact that the total parenteral nutrition was found to be 
devoid of Cr3+, it was supplemented with Cr3+.  Addition of Cr3+ to the nutrition 
regimen for two weeks normalized the patient’s glucose tolerance, and this 
supplementation reduced insulin requirements and subsided peripheral 
neuropathy in the following five months of hospitalization (239).  
Several additional studies have supported the concept of Cr3+ essentiality in 
humans by showing that Cr3+ supplementation resulted in similar beneficial 
effects in other hyperglycemic patients (240-242). In further support of Cr3+ 
essentiality, evidence suggests that Cr3+ deficiency can lead to defects 
characteristic of cardiovascular disease such as elevated serum cholesterol, 
elevated triglycerides and decreased HDL levels (243-245). It is important to note 
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that Cr3+ has been well documented to have beneficial effects in diabetic animals 
and humans. As mentioned above, the essentiality of Cr3+ and effects on glucose 
metabolism in healthy animals has come into question based on findings in lean 
healthy rats (238, 246). These findings further support the concept that Cr3+ 
action is dependent upon the diabetic milieu. Nevertheless, increasing Cr3+ 
content in the diet of these healthy rats significantly improved insulin sensitivity 
(238), which suggests a beneficial effect of Cr3+ on glucose metabolism.  
Nutritional Cr3+ in the trivalent form is found in a variety of foods such as 
brewer’s yeast, whole grains, meats and vegetables. The popularity of Cr3+ 
supplements is significant, as chromium picolinate (CrPic) supplements are 
currently the second highest-selling health supplement behind sales of calcium 
supplements (247). Unlike hexavalent chromium (Cr6+), which is a byproduct of 
stainless steel and pigment processing and is classified as carcinogenic for 
humans (248), Cr3+ is known to be stable and relatively non-toxic with a large 
safety range (249). A variety of forms of Cr3+ are ingested including chromium 
yeast (CrY), chromium chloride (CrCl3) and CrPic, the most stable and 
bioavailable form of Cr3+ (250). Recently pharmacological compounds and Cr3+ 
complexes have been introduced such as chromium nicotinate/niacin (CrN) 
(251), chromium (D-phenylalanine)3 (Cr(D-Phe)3) (252), and chromium citrate 
(CrCIT) (253). These newly-designed forms of Cr3+ have been demonstrated to 
have beneficial effects on glucose and lipid metabolism (252, 254-258) and 
appear to be specific for Cr3+ as opposed to other minerals such as magnesium, 
manganese and iron. Together these fundamental findings demonstrate the 
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potential value of Cr3+ as a micronutrient and prompted future research efforts to 
determine the cellular and molecular mechanism(s) of Cr3+ action that impact 
glucose and lipid metabolism.   
 
 I.D.2. Effects of Cr3+ on glucose and lipid metabolism 
Several in vivo studies have started to characterize the impact of Cr3+ on 
regulatory mechanisms of glucose and lipid metabolism and the basis for Cr3+’s 
nutritive value. In spite of these arduous efforts since the original concept of Cr3+ 
essentiality, the mechanism(s) of Cr3+ action are still not completely understood 
nearly fifty years later (259). Animal and human studies have provided 
encouraging findings regarding the effects of Cr3+ in T2D (260-263). Several 
studies have demonstrated beneficial effects of Cr3+ on glucose metabolism, lipid 
metabolism and specifically insulin sensitivity in a variety of genetic and 
streptozotocin/alloxan-induced diabetic mouse (264) and rat models (253, 263, 
265-268). Furthermore, studies have also shown that Cr3+ supplementation 
improves insulin sensitivity in hyperinsulinemic, insulin-resistant (262, 269) and 
diet-induced insulin-resistant rats (270). In addition, animal studies have shown 
that maternal chromium restriction induces glucose intolerance (271) and 
adiposity (272) in offspring, and deficiency of dietary Cr3+ can disrupt insulin 
sensitivity (273, 274).  
An association between Cr3+ status and insulin resistance in humans has also 
been demonstrated (275). Several studies of Cr3+ supplementation in humans 
have yielded encouraging results regarding the clinical impact of this 
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micronutrient. For example, multiple human studies demonstrate that Cr3+ 
supplementation can improve aspects of glucose and lipid metabolism in patients 
with T2D. Interestingly, taken together the available human data seem to suggest 
that Cr3+ supplementation is most effective in T2D patients (276-280) compared 
to obese, insulin-resistant patients at risk for T2D (281-283). Adding another level 
of complexity to the observations of Cr3+ action in humans, it has been recently 
proposed that patient phenotype can be important in predicting clinical response 
(284), and that humans  can potentially be classified into “responders” and “non-
responders” based on prior T2D progression and glucose metabolism variables 
(285, 286). Regardless of the contradictory findings in humans studies with 
various strengths and weaknesses in study design (250, 287, 288), a recent 
meta-analysis conducted through August 2006 concluded that Cr3+ significantly 
improves glycosylated hemoglobin by -0.6% (-0.9 to -0.2) and fasting glucose by 
-1.0 mM (-1.4 to -0.5) in T2D subjects (289). No significant effect was found in 
people without diabetes, in accord with our in vitro findings described below that 
Cr3+-effectiveness is contingent on the presence of a diabetic milieu (23). 
 
I.D.2. Cellular and molecular mechanisms of Cr3+ action 
 Several mechanisms have been proposed for the interactions between Cr3+ 
and insulin action. For example, studies have shown a direct interaction of Cr3+ 
with insulin (290, 291). In addition, it has been shown that Cr3+ enhances insulin 
action by increasing IR number (292) and increasing the tyrosine kinase activity 
of IRs that have been previously activated by insulin (293, 294). Studies have 
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implicated transferrin in the transport of Cr3+ from the blood to insulin-sensitive 
tissues, as the loading of transferrin with Cr3+ has been demonstrated in vitro 
(295) and is increased following addition of Cr3+ to the bloodstream (296). 
Interestingly, insulin has been shown to stimulate the movement of transferrin 
receptors to the PM, which supports the idea that transferrin may deliver Cr3+ to 
insulin-sensitive tissues from the blood upon insulin stimulation (297, 298). 
However, the mechanisms involved in Cr3+ transport and interactions with 
transferrin are not completely understood. A naturally occurring oligopeptide 
known as low-molecular weight chromium-binding substance, or chromodulin, 
has been demonstrated to bind chromic ions in response to the insulin-stimulated 
activation of IR (293, 299). Chromodulin and its binding to chromium have 
recently been characterized after many years of arduous efforts to further 
understand this mediator in chromium action (300). The binding of chromodulin 
to chromic ions was shown to robustly stimulate IR’s tyrosine kinase activity in 
the presence of insulin. Stimulation of IR activity induced by this binding event 
would be expected to increase insulin-stimulated GLUT4 translocation to the PM, 
as has been previously observed (22, 262). However, the insulin signaling 
mediators involved in this process have not been identified.  
In further support of Cr3+ positively impacting GLUT4 regulation, published 
studies from our group demonstrate that Cr3+ at a clinically efficacious dose 
mobilized GLUT4 to the PM and enhanced insulin-stimulated glucose transport in 
3T3-L1 adipocytes (22). Cr3+ did not increase the activation states of any known 
signaling mediators of insulin action. Reports have shown that Cr3+ increases 
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membrane fluidity and the rate of insulin internalization (301). While insulin-
stimulated GLUT4 translocation does not appear to require insulin first being 
transported into the cell (302), studies have suggested that IR internalization may 
function to compartmentalize and promote efficient interaction with downstream 
insulin signaling substrate(s) associated with internal cellular membranes (303-
305). In line with an effect of Cr3+ on membrane fluidity (301), our group has 
shown that Cr3+ treatment decreases PM cholesterol in 3T3-L1 adipocytes (22). 
Mechanistically, Cr3+ action was rendered ineffective by replenishment of cells 
with exogenous cholesterol (22). Since Cr3+ has the greatest benefit on glucose 
metabolism in hyperglycemic insulin-resistant individuals (289), we tested if this 
PM cholesterol-lowering Cr3+ effect was dependent on the diabetic milieu. 
Studies revealed that the GLUT4 redistribution to the PM in 3T3-L1 adipocytes 
treated with Cr3+ only occurred in cells cultured under high glucose (25 mM) 
conditions and not in cells cultured under non-diabetic (5.5 mM glucose) 
conditions (23). Cr3+ selectively lowered excess PM cholesterol in the high 
glucose cells, which contained more PM cholesterol than low glucose cells (23). 
New data from our group also suggest that Cr3+ protects against 
hyperinsulinemia-induced cholesterol accrual in 3T3-L1 adipocytes (24).  
The actions of Cr3+ on PM cholesterol levels described in this subsection are 
consistent with its effects on membrane fluidity. As described above, moderate 
changes in membrane fluidity have been shown to increase glucose transport 
(228). In addition, augmentation of membrane fluidity has been documented to 
further increase basal glucose transport in fat cells, which is not fully active under 
45 
 
basal conditions (306). Interestingly, the antidiabetic drug metformin has also 
been shown to increase membrane fluidity and subsequently enhance insulin 
action (307, 308). Similarly to Cr3+, this effect of metformin on membrane fluidity 
may underlie the mechanism by which metformin increases GLUT4 translocation 
(309, 310).  
While studies reviewed in this section suggest that Cr3+ positively impacts 
GLUT4 via PM cholesterol lowering and potentially other cellular/molecular 
mechanisms, the antidiabetic actions of Cr3+ against hyperinsulinemia- and 
obesity-induced insulin resistance in skeletal muscle have not been studied 
extensively either in vitro or in vivo. Furthermore, whether Cr3+ improves 
cholesterol-based aspects of GLUT4 regulation (e.g. F-actin) is not known. 
Although Cr3+ is thought to be an essential nutrient in animals and humans by 
optimizing glucose and lipid metabolism, much work remains to dissect the 
mechanism(s) by which Cr3+ may have nutritional value. The rationale for 
dissecting mechanism(s) of Cr3+ action in this thesis research is that once the 
biochemical basis for Cr3+ action is completely dissected, its use as a supplement 
could be optimized and/or development of pharmacologically innovative 
approaches to the prevention and treatment of glucose/lipid metabolism 
disorders could be initiated.   
With regards to Cr3+, it is of further interest that AMPK activity has been 
observed to be increased in Cr3+-treated cells or tissues from Cr3+-supplemented 
animals (22, 24, 255, 311-315). Interestingly, it was recently demonstrated that 
Cr3+-mediated activation of AMPK is involved in Cr3+ inhibiting the release of 
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resistin, which has been implicated in insulin resistance, in insulin-resistant 3T3-
L1 adipocytes (311). Given the importance of membrane cholesterol regulation in 
insulin action and the development of insulin resistance, of interest is the fact that 
AMPK phosphorylates/inhibits HMGR, the rate-limiting enzyme in cholesterol 
synthesis. Arduous research efforts have focused on identifying cellular targets of 
therapeutic interest and new drug therapies to prevent or slow the progression of 
insulin resistance in obesity and T2D. AMPK represents a promising cellular 
target that has received much attention in the contexts of obesity, insulin 
resistance, dyslipidemia and T2D. The following section will focus on studies 
implicating AMPK in the regulation of glucose transport and cholesterol 
synthesis. This section will outline AMPK structure/function, AMPK regulation of 
insulin action and downstream cellular targets of AMPK that are of therapeutic 
interest in the treatment and/or prevention of insulin resistance.  
 
 I.E. AMPK Regulation of Glucose Transport and Cholesterol Synthesis 
As described above, a major challenge in curbing the epidemics of obesity 
and T2D involves a lack of physical activity in the developed world in the face of 
overeating. It is well documented that physical exercise has positive effects on 
glucose homeostasis in healthy individuals as well as those with T2D (316, 317). 
The benefits of exercise are based on the concept that muscle contraction is 
known to be a potent stimulus of glucose transport (318, 319) and has been 
shown to increase skeletal muscle insulin sensitivity (320-323). The insulin-
sensitizing effects of exercise in skeletal muscle are significant as skeletal 
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muscle is responsible for a large majority of post-prandial glucose disposal (29) 
and is regarded as a major site of insulin resistance (28). The mechanism(s) by 
which exercise elicits these effects on glucose transport and insulin sensitivity is 
not completely understood; however, several effectors have been implicated in 
contraction/exercise-induced glucose transport. These putative mechanisms 
include, but are not limited to, calcium (53, 324, 325), nitric oxide (NO) (326, 
327), bradykinin (328, 329) and AMPK (324, 330, 331). Studies have now 
established AMPK as a central player of the energy-sensing mechanisms 
involved in contraction/exercise-stimulated glucose transport. In addition to 
contraction/exercise, AMPK has also been proposed as a mediator of insulin-
sensitizing and antidiabetic therapies such as metformin (332, 333), resveratrol 
(334-337), epigallocatechin gallate (338, 339), berberine (340-342), bitter melon 
(343), the plant sterol β-sitosterol (344), nigella sativa seed ethanol extract (345) 
and Cr3+  (22, 24, 255, 311-315). AMPK has also been shown to be involved as a 
mediator of the actions of insulin-sensitizing adipokines and cytokines such as 
adiponectin (346-348), leptin (349, 350) and IL-6 (348, 351-353). Taken together, 
our current understanding of AMPK-based regulation of insulin sensitivity and 
glucose transport in skeletal muscle establishes AMPK as a therapeutic target of 
interest for insulin resistance and T2D. 
 
I.E.1. AMPK Structure and Regulation 
AMPK has been referred to as a “fuel gauge” for maintaining cellular energy 
regulation (354).  AMPK is a heterotrimeric Ser/Thr protein kinase and is 
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conserved from yeast to humans (355, 356). This kinase is composed of three 
subunits; a catalytic α subunit and regulatory β and γ subunits (357). AMPK is 
found in many tissues throughout the body (358) and functions as an energy 
sensor to maintain cellular energy homeostasis (330, 359). One isoform of the α 
subunit is the α1 isoform. Complexes containing α1 are ubiquitously expressed, 
while α2-containing complexes are more highly expressed in skeletal muscle, 
heart and liver (360-362). These isoforms are thought to play different roles in 
maintaining cellular energy homeostasis due to variations in their target 
specificity and cellular locations (363, 364). Kinase activity is primarily possessed 
by the α subunit, but the β and γ subunits contribute to regulation of kinase 
activity along with their roles in stabilizing the heterotrimeric kinase complex 
(362). The β subunit contains a glycogen binding domain that is associated with 
inhibition of AMPK when glycogen is bound (365-367). In addition, the γ subunit 
contains cystathionine-β-synthase (CBS) binding domains that are important for 
binding molecules containing adenosine (368). CBS binding domains specifically 
bind 5’ adenosine monophosphate (AMP), which results in allosteric activation of 
AMPK (369). 
AMPK is activated in skeletal muscle by cellular energy stresses that lead to 
depletion of high-energy molecules such as 5’ adenosine triphosphate (ATP), 
phosphocreatine and glycogen. An increase in the AMP/ATP ratio results in 
accumulated AMP binding to the CBS domain of the γ subunit (369) and subtly 
increases kinase activity of AMPK. Along with this allosteric activation, AMP 
binding also causes a conformational change that favors the α subunit’s 
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activation loop being targeted by upstream kinases on Thr172 (370-372). Two 
kinases, including LKB1 (373-375) and calmodulin-dependent protein kinase 
kinase β (CaMKKβ) (376, 377) have been implicated as the kinases upstream of 
AMPK that target Thr172. Phosphorylation of AMPK at Thr172 has been shown 
to be essential for kinase activity (371, 378, 379), and phosphorylation levels are 
highly associated with kinase activity level (379).    
 
I.E.2. Downstream Targets of AMPK 
AMPK induces both acute and chronic metabolic adaptations once it 
becomes activated to restore cellular energy homeostasis. Acutely, AMPK 
directly regulates downstream targets by phosphorylation. Chronic effects of 
AMPK activation involve regulating expression of genes involved in glucose and 
lipid metabolism (380-383), for example. Activation of AMPK is now recognized 
as being partially responsible for health benefits from exercise (384). Similarly to 
endurance training, AMPK elicits adaptive metabolic responses such as 
increased uptake and metabolism of glucose and FAs. AMPK has also been 
shown to regulate enzymes central to the catabolism of glucose and FAs, 
including mitochondrial enzymes (380-383, 385-388). AMPK activation acutely 
functions to restore cellular energy homeostasis by inhibiting anabolic pathways 
that consume energy and activating catabolic pathways that increase energy in 
the cell (specifically ATP) (330, 354). It is well documented that AMPK 
phosphorylates the downstream target acetyl-CoA carboxylase (ACC) on Ser79. 
Phosphorylation of ACC by AMPK inhibits this enzyme resulting in a switch from 
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synthesizing to oxidizing FAs. Inhibition of ACC by AMPK-mediated 
phosphorylation decreases the product of this enzyme, malonyl-CoA, a key 
intermediate in FA synthesis (389-391). Furthermore, it has been demonstrated 
that AMPK activation results in activation of malonyl-CoA decarboxylase, which 
further depletes malonyl-CoA levels (392). The decrease in malonyl-CoA levels 
relieves the inhibition of carnitine palmitoyltransferase 1 (CPT-1), which allows 
for increased transport of FAs into the mitochondria for oxidation (393-396). The 
increased FA oxidation is also accompanied by a reciprocal decrease in the 
amount of substrate for FA esterification. 
Another important downstream target that is phosphorylated by AMPK at 
Ser872 is HMGR (397-399). Of interest is the fact that AMPK can directly 
inactivate the rate limiting enzyme in cholesterol synthesis and decrease lipid 
biosynthesis given our understanding of how cellular cholesterol accrual perturbs 
GLUT4 regulation and insulin sensitivity. AMPK-based regulation of cholesterol 
synthesis will be described below in more detail. Explored in the next section are 
fundamental findings that begin to dissect how AMPK regulates glucose transport 
and set the stage for our studies to determine the role of membrane cholesterol 
in AMPK and Cr3+ action.    
 
I.E.3. AMPK Regulation of Glucose Transport 
As described in detail above, muscle contraction during exercise is known to 
stimulate glucose transport (318, 319) and increase skeletal muscle insulin 
sensitivity (320-323). Furthermore, AMPK activation has been demonstrated to 
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acutely increase glucose transport in skeletal muscle both in vivo and in vitro 
(400-409). Specifically, AMPK activation increases glucose transport in skeletal 
muscles obtained from animal models (402) (400, 401) and cultured skeletal 
muscle myotube lines such as L6 (403-406), C2C12 (407) and H-2K (408, 409). 
This insulin-mimetic stimulation of glucose transport by AMPK has been shown 
to be mediated by increased GLUT4 delivery and accumulation in the PM (410). 
However, the exact mechanisms by which AMPK activation acutely affects 
GLUT4 regulation and insulin sensitivity are not fully understood. In addition to its 
insulin mimetic actions, AMPK has also been shown to have insulin-sensitizing 
effects (411-413). Putative mechanisms tying AMPK’s insulin-mimetic and 
insulin-sensitizing actions to GLUT4 trafficking will be described in detail below.  
In addition to acutely stimulating glucose transport, AMPK activation expands 
the long-term cellular capacity for glucose transport and oxidation by positively 
regulating transcription of genes involved in these processes (414). For example, 
AMPK activation has been shown to positively regulate transcription of GLUT4 
(381, 400, 415, 416), citrate synthase, succinate dehydrogenase (385), 
cytochrome C and peroxisome proliferator-activated receptor gamma, coactivator 
1 alpha (PGC-1α) (417-419). Mechanisms involved in the AMPK-mediated 
increase in GLUT4 expression include the specific activation of transcription 
factors such as myocyte enhancer factor-2 (MEF-2), GLUT4 enhancer factor 
(GEF) (420) and nuclear respiratory factor 1 (NRF1) (382, 421).  
A well-accepted hypothesis relating AMPK activation to GLUT4 accumulation 
in the PM involves AMPK-mediated phosphorylation of AS160/TBC1D4 and its 
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homolog TBC1D1. These Rab GAPs, which are distal players in the insulin 
signaling pathway of GSV recruitment, are emerging as a putative nexus 
between the AMPK and insulin signaling pathways to explain the insulin-mimetic 
and insulin-sensitizing actions of AMPK. AMPK activation and insulin have both 
been shown to increase phosphorylation levels of TBC1D4 and TBC1D1 (422-
424) to regulate GSV trafficking (37, 331). Study has shown that mutation of 
these putative phosphorylation residues on TBC1D4 prevents AMPK’s insulin-
mimetic action (37). In further support of AMPK’s dual actions on mimicking and 
sensitizing insulin action, recent kinetic evidence demonstrates that AMPK can 
regulate a separate pool of GLUT4 as insulin to further potentiate PM GLUT4 
accumulation and glucose transport (404).  
Mechanistically, AMPK has well accepted roles in cellular, tissue-specific and 
whole body energy balance (359). AMPK knockout studies have been helpful in 
establishing roles for AMPK isoforms in skeletal muscle. Whole body knockout of 
the AMPK α2 subunit prevented pharmacological AMPK activation-induced 
increases in skeletal muscle glucose uptake, while knockout of the α1 subunit 
had no effect (425). In addition, mice lacking the α1 isoform present no defect in 
glucose homoeostasis, as assessed by glucose tolerance testing (426). In 
support of a role for the AMPK α2 subunit regulating glucose homeostasis, mice 
lacking the α2 isoform clearly exhibit reduced insulin sensitivity (426) and the α2 
isoform is the major catalytic isoform expressed in skeletal muscle (360, 362). 
The role of AMPK in insulin resistance has been studied using muscle-specific 
transgenic mice expressing an inactive form of the AMPK α2 catalytic subunit 
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(427). These studies demonstrated that ablation of muscle AMPK α2 activity 
worsens the glucose intolerance induced by high fat (HF) feeding. This 
exacerbated glucose intolerance was associated with a decrease in insulin-
stimulated muscle glucose transport, measured in isolated muscles in vitro (427). 
Together these results demonstrate that AMPK α2 activity is an important factor 
contributing to insulin action on glucose transport in skeletal muscle.  While the 
mechanisms linking AMPK to glucose transport outlined in this subsection are 
still not completely understood, an appreciation is emerging for the role of AMPK-
mediated regulation of cellular cholesterol in modulating insulin sensitivity. 
Recent work from our group has provided evidence that targeting AMPK may be 
beneficial for cholesterol-based aspects of GLUT4 dysregulation in insulin 
resistance. 
 
I.E.4. AMPK Regulation of Cholesterol Synthesis 
As described above, an important downstream target phosphorylated by 
AMPK at Ser872 is HMGR (397-399). HMGR is the rate-limiting enzyme in 
cholesterol synthesis, and phosphorylation of HMGR at Ser872 inhibits this 
enzyme to shut off cholesterol biosynthesis. AMPK is well appreciated to play 
roles in improving plasma lipids and cellular lipid stores (359, 428). While 
regulation of cellular cholesterol is a tightly controlled process in mammalian 
cells, cellular cholesterol accrual can become dysregulated in states of obesity 
and insulin resistance as detailed above. For example, tissues obtained from 
insulin-resistant mice, rats, swine and humans all display an increase in 
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membrane cholesterol content (10). Exposure of adipocytes and skeletal muscle 
cells to excess glucose, insulin and FAs has been shown to induce membrane 
cholesterol accrual (10, 11, 23, 24). Recent evidence suggests that AMPK 
activation and Cr3+, potentially via activation of AMPK, can restore elevated 
cellular membrane cholesterol in insulin-resistant 3T3-L1 adipocytes leading to 
beneficial effects on cellular cholesterol efflux machinery (24). Furthermore, our 
group recently determined that treatment of L6 skeletal muscle myotubes with 
excess FA’s results in an increase in membrane cholesterol content that perturbs 
GLUT4 regulation and involves increased expression of Hmgcr, the gene that 
encodes for HMGR (10).   
Based on the hypothesis that AMPK and Cr3+ action inhibit cholesterol 
synthesis via phosphorylation of HMGR and may improve key 
membrane/cytoskeletal parameters of insulin sensitivity, my thesis research 
explored the potential role(s) of the AMPK-HMGR cholesterol regulatory axis in 
Cr3+ action and control of PM GLUT4 accumulation. An improved mechanistic 
understanding of how AMPK and Cr3+-induced AMPK activity affect 
membrane/cytoskeletal aspects of GLUT4 regulation and dysregulation in insulin 
resistance is of paramount importance because it opens novel cellular avenues 
for nutritional AMPK-targeted therapies for insulin resistance and T2D. 
 
 I.F. Thesis Hypothesis and Specific Aims   
Based on the fundamental research findings described above and current gap 
in understanding regarding the mechanism(s) of chromium action, especially in 
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skeletal muscle, I formulated the following hypothesis for my thesis research.  My 
central hypothesis is that chromium, via AMPK activation, protects against 
GLUT4 and glucose transport dysfunction in skeletal muscle cells by protecting 
against membrane cholesterol accrual that induces F-actin loss and insulin 
resistance.  Furthermore, I hypothesized that the actions of chromium and AMPK 
would improve skeletal muscle insulin sensitivity and glucose metabolism in vivo.  
Using cellular and animal models of insulin resistance, I tested my central 
hypothesis by pursuing the following two specific aims:   1) To define chromium’s 
action(s) against membrane/cytoskeletal derangements and insulin resistance; 
and 2) to dissect the mechanism(s) by which AMPK activity positively impacts 
GLUT4 regulation. 
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Chapter II.  Results 
 
II.A. AMPK is Involved in a Membrane/Cytoskeletal Pathway of Chromium 
Action that Improves Glucose Transport Regulation in Insulin-Resistant 
Skeletal Muscle Cells 
 
II.A.1. Summary 
A recent review of randomized controlled trials found that Cr3+ 
supplementation significantly improved glycemia among patients with diabetes, 
consistent with a long-standing appreciation that this micronutrient optimizes 
carbohydrate metabolism. Nevertheless, a clear limitation in the current evidence 
is a lack of understanding of Cr3+ action. Here we tested if increased AMPK 
activity, previously observed in cells treated with Cr3+ or tissues from animals 
supplemented with Cr3+, mediates improved glucose transport regulation under 
insulin-resistant hyperinsulinemic conditions. In L6 myotubes stably expressing 
the glucose transporter GLUT4 that carries an exofacial myc-epitope tag, acute 
insulin-stimulation (20 min, 100 nM) increased GLUT4myc translocation by 69% 
and glucose uptake by 97%. In contrast, a hyperinsulinemic state, induced by 
inclusion of 5 nM insulin in the medium for 12 h, impaired stimulation of these 
processes by insulin. Consistent with Cr3+’s beneficial effects on glycemic status, 
supplementing the medium with 100 nM chromium picolinate (CrPic) for 16 h 
restored insulin’s ability to fully regulate GLUT4myc translocation and glucose 
transport. The insulin-resistant myotubes did not display impaired insulin 
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signaling, nor did CrPic amplify insulin signaling. However, CrPic normalized 
elevated membrane cholesterol that impaired cortical F-actin structure. 
Mechanistically, data support that CrPic lowered membrane cholesterol via 
AMPK. Consistent with this data, siRNA-mediated AMPK silencing blocked 
CrPic’s beneficial effects on GLUT4 and glucose transport regulation. These data 
identify a mechanism by which Cr3+ may positively impact glycemic status, 
thereby stressing a plausible, essential action of this micronutrient in glucose 
homeostasis. 
 
II.A.2. Results 
Cr3+ protects against hyperinsulinemia-induced GLUT4/glucose 
transport dysfunction:  We first performed studies to determine if Cr3+ protects 
against hyperinsulinemia-induced insulin resistance in skeletal muscle cells using 
the L6-GLUT4myc myotube cell system. The L6 myotube cell line stably 
expresses GLUT4 carrying a myc epitope on the first exofacial domain of GLUT4 
and allows for detection of GLUT4 transporters at the PM with glucose transport 
functionality (429). This myc-tagged transporter segregates, cycles, and 
responds to insulin similarly to endogenous GLUT4 (430, 431). Myotubes 
cultured with or without hyperinsulinemia (12 h, 5 nM) and/or CrPic (16 h, 100 
nM) were left untreated or acutely stimulated with insulin (20 min, 100 nM) to 
determine the ability of insulin to stimulate GLUT4 translocation to the PM. As 
shown in Figure 2A, myc epitope labeling at the PM was increased 69% 
(P<0.05, compare bars 1 and 2) in response to acute insulin stimulation.
58 
 
0
1
2
3
4
*
*#
*
*#
ns
20' Insulin   -      +      -      +      -      +      -      +
C
rP
ic
C
rP
ic
C
rP
ic
C
rP
ic
P
M
 G
L
U
T
4
m
y
c
IF
:
m
y
c
/
n
u
c
le
i
A
B
0
1000
2000
3000
20' Insulin    -      +      -     +     -      +      -      +
*
*#
ns
**
C
rP
ic
C
rP
ic
C
rP
ic
C
rP
ic
2
-d
e
o
x
y
-D
-g
lu
c
o
s
e
 t
ra
n
s
p
o
rt
(d
p
m
 /
 m
g
 p
ro
te
in
 /
 m
in
)
Control
12 h Insulin
  
 
 
 
 
Figure 2. Cr3+ protects against hyperinsulinemia-induced GLUT4/glucose 
transport dysfunction. L6-GLUT4myc myotubes were pretreated without (white 
bars) or with (black bars) 5 nM insulin for 12 h in the absence or presence of 100 
nM CrPic, which was added to the culturing medium 4 h before the 12-h insulin 
pretreatment for a total time of 16 h. After the 16-h and 12-h pretreatments, cells 
were either left untreated (A, panels 1, 3, 5, and 7) or treated (A, panels 2, 4, 6, 
and 8) with 100 nM insulin for 20 min.  GLUT4myc immunofluorescence (A) was 
assessed and normalized using Syto 60 nuclear stain. Mean values ± SEM of 
GLUT4myc are shown from 6-7 independent experiments. All insulin-stimulated 
GLUT4myc values were significantly (*, P<0.05) elevated over their respective 
controls. *#, P<0.05 vs. insulin-stimulated control. For 2-DG uptake experiments 
(B), cells were pretreated as described above. After the 16-h and 12-h 
pretreatments, cells were either left untreated (B, panels 1, 3, 5, and 7) or treated 
(B, panels 2, 4, 6, and 8) with 100 nM insulin for 20 min. 2-DG transport values 
were normalized to protein content in each sample. Mean values ± SEM of 2-DG 
transport are shown from 6-7 independent experiments. All insulin-stimulated 2-
DG transports were significantly (*, P<0.05) elevated over their respective 
controls. *#, P<0.05 vs. insulin-stimulated control.  
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The ability of insulin to stimulate GLUT4 translocation was inhibited by ~50% 
(P<0.05) in myotubes exposed to hyperinsulinemia compared to insulin-
stimulated control myotubes (compare bars 2 and 4). Neither hyperinsulinemia 
nor CrPic had no significant effect on basal PM GLUT4 detection (compare bars 
1, 3, and 5); however, CrPic-treated myotubes displayed a 16% (P<0.05) 
increase in insulin-stimulated PM GLUT4 levels versus control insulin-stimulated 
myotubes (compare bars 2 and 6). Importantly, CrPic protected against the 
hyperinsulinemia-induced loss in GLUT4 regulation by insulin (compare bars 2, 
4, and 8). To directly test the ability of these PM-localized GLUT4 transporters to 
transport glucose following the acute insulin stimulation, we performed 2-deoxy-
D-glucose (2-DG) uptake assays (Fig. 2B). Glucose transport was increased 
97% (P<0.05; compare bars 1 and 2) in response to acute insulin stimulation. 
The ability of insulin to stimulate glucose transport was inhibited by 67% (P<0.05) 
in myotubes exposed to hyperinsulinemia compared to insulin-stimulated control 
myotubes (compare bars 2 and 4) with no change in basal glucose transport 
levels (compare bars 1 and 3). CrPic had no significant effect on basal or insulin-
stimulated glucose transport rate in control myotubes (compare bars 1 and 5 and 
2 and 6). However, and in line with the measured increase in PM GLUT4, CrPic 
restored the hyperinsulinemia-induced loss in glucose transport regulation by 
insulin (compare bars 2, 4, and 8). 
 
Cr3+ suppresses PM cholesterol accrual accompanying cortical F-actin 
loss:  Previously we documented F-actin loss in these myotubes contributed to 
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insulin-induced insulin resistance (8). We now find in this hyperinsulinemic cell 
model of insulin resistance that a 20% (P<0.05) increase in PM cholesterol 
accompanies the 11% (P<0.05) decrease in F-actin (Figs. 3A and 3B, bars 2). 
Moreover, these hyperinsulinemia-induced changes were prevented by CrPic 
treatment (Fig. 3A and 3B, bars 4) with no effect in control myotubes (bars 3). 
To probe this observation further, we next tested the effect of zaragozic acid A 
(ZA), which inhibits the enzyme squalene synthase downstream of HMGR and 
effectively blocks cholesterol synthesis (432). An advantage to using this strategy 
versus direct blockade of HMGR activity with a statin is that statins have recently 
been reported to also increase AMPK activity (433). Similarly to CrPic, ZA (16 h, 
10 µM) pretreatment protected against hyperinsulinemia-induced PM cholesterol 
accrual and F-actin loss (Figs. 4A and 4B, bars 4) with no effect observed in 
control myotubes (bars 3). Consistent with these hyperinsulinemia induced 
membrane/cytoskeletal changes and insulin resistance being corrected by the 
cholesterol-lowering action of Cr3+, ZA treatment protected against the 
hyperinsulinemia-induced loss in insulin-stimulated GLUT4 translocation (Fig. 
4C, compare bars 2, 3, and 5). ZA tended to increase PM GLUT4 in control 
myotubes (compare bars 2 and 4) similarly to CrPic; however this did not reach 
statistical significance. 
 
Insulin signaling-independent action of Cr3+:  Our previous studies suggested 
that neither hyperinsulinemia exposure nor effects of CrPic could be attributed to
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Figure 3. Cr3+ protects against hyperinsulinemia-induced 
membrane/cytoskeletal derangements. L6-GLUT4myc myotubes were 
pretreated without (white bars) or with (black bars) 5 nM insulin for 12 h in the 
absence or presence of 100 nM CrPic, which was added to the culturing medium 
4 h before the 12-h insulin pretreatment for a total time of 16 h. Cholesterol 
measurement following membrane fractionation (A) and quantification of 
immunofluorescent labeling of F-actin (B) were determined, respectively. Mean 
values ± SEM of membrane cholesterol and F-actin are shown from 4-11 
independent experiments.  *, P<0.05 vs. control. 
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Figure 4. Cholesterol synthesis inhibition protects against 
hyperinsulinemia-induced membrane/cytoskeletal derangements and 
insulin resistance. L6-GLUT4myc myotubes were pretreated without (white 
bars) or with (black bars) 5 nM insulin for 12 h in the absence or presence of 10 
µM zaragozic acid A (ZA), which was added to the culturing medium 4 h before 
the 12-h insulin pretreatment for a total time of 16 h. Cholesterol measurement 
following membrane fractionation (A) and quantification of immunofluorescent 
labeling of F-actin (B) were determined, respectively. Mean values ± SEM of 
membrane cholesterol and F-actin are shown from 3-4 independent experiments.  
*, P<0.05 vs. control. To assess the effects of ZA on hyperinsulinemia-induced 
GLUT4 dysregulation, cells were pretreated as described in Figure 2. After the 
16-h and 12-h pretreatments, cells were either left untreated or treated with 100 
nM insulin for 20 min and GLUT4myc immunofluorescence was determined (C). 
Mean values ± SEM of GLUT4myc are shown from 3 independent experiments. 
Insulin-stimulated GLUT4myc were significantly (*, P<0.05) elevated over their 
respective controls. *#, P<0.05 vs. insulin-stimulated control. 
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decreases or increases, respectively, in insulin signaling (7, 8, 22, 23), although 
studies have suggested that CrPic amplifies insulin signaling (294, 434, 435). 
Therefore, we further evaluated key insulin signaling parameters of insulin action. 
As previously reported in this model system (8), hyperinsulinemia did not impair 
basal or insulin-stimulated phosphorylation of Akt2 (Fig. 5A, compare bars 1-4) 
or phosphorylation of its downstream substrate AS160 (Fig. 5B, compare bars 1-
4). In addition, similar to published observations in 3T3-L1 adipocytes (22), CrPic 
treated control or hyperinsulinemic cells did not display any change in basal or 
insulin-stimulated phosphorylation of Akt2 or AS160 (Figs. 5A and 5B, bars 4-8). 
 
Increased AMPK activity mediates Cr3+ action:  Consistent with previous 
observations in Cr3+-treated cells (22, 24, 311-313) or tissue from Cr3+-
supplemented animals (255, 314, 315), AMPK activity was increased  as 
evidenced by increased phosphorylation of the catalytic alpha subunit at Thr172 
(Fig. 6A, compare bars 1 and 2). Although this increase was very slight (14%) it 
was statistically significant. Treatment with hyperinsulinemia had no significant 
effect on Thr172 phosphorylation (Fig. 6A, compare bars 1 and 3). Consistent 
with the concept that Cr3+ action is dependent on the diabetic milieu, we 
observed that CrPic-induced phosphorylation of AMPK was 30% (P<0.05) more 
robust in hyperinsulinemia-induced insulin-resistant myotubes compared to 
control myotubes (Fig. 6A, *P<0.05; compare bars 2 and 4). The maximal 
increase in AMPK activity observed in CrPic-treated myotubes exposed to 
hyperinsulinemia is more similar to the level of AMPK phosphorylation we
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Figure 5. Insulin signaling-independent action of Cr3+. Cells were treated as 
described in Figure 2. After the 16-h and 12-h pretreatments, cells were either 
left untreated (panels 1, 3, 5, and 7) or treated (panels 2, 4, 6, and 8) with 100 
nM insulin for 5 min. After treatment, whole-cell lysates were prepared and 
subjected to Western blot analyses to assess Akt2(Ser474) phosphorylation (A), 
phospho-Akt substrate phosphorylation (B), and β-actin (C). White bars and 
black bars represent control and hyperinsulinemic groups, respectively. 
Immunoblots shown in A and B are representative of 3-8 experiments, and all 
quantitated values presented as means ± SEM from # 3-8 experiments were 
determined by densitometry and normalized to total protein (Akt2, AS160). All 
insulin-stimulated values were significantly (*, P<0.05) elevated over their 
respective controls. 
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Figure 6. Cr3+ increases activation of AMPK.  Cells were treated as described 
in Figure 3. After treatment, whole-cell lysates were prepared and subjected to 
Western blot analyses to assess AMPK(Thr172) phosphorylation (A) and 
ACC(Ser79) phosphorylation (B). White bars and black bars represent control 
and hyperinsulinemic groups, respectively. Immunoblots shown in A and B are 
representative of 5 independent experiments, and all quantitated values 
presented as means ± SEM from 5 independent experiments were determined 
by densitometry and normalized to total protein (AMPK and ACC, respectively). *, 
P<0.05 vs. respective control.   
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observe with the widely-used experimental activator of AMPK, 5-aminoimidazole-
4-carboxamide-1-beta-D-ribonucleoside (AICAR). To confirm that CrPic 
treatment increased AMPK activity, we next determined the effect of CrPic on 
phosphorylation of acetyl-CoA carboxylase (ACC) at serine residue 79 (Ser79), a 
well characterized downstream substrate of AMPK. Fig. 6B shows that CrPic 
induced a similar 17% increase (P<0.05) in phosphorylation of ACC at Ser79 in 
CrPic-treated myotubes compared to control (compare bars 1 and 2), and 
hyperinsulinemia had no significant effect on ACC Ser79 (compare bars 1 and 3). 
In line with our AMPK Thr172 findings, CrPic treatment robustly increased 
phosphorylation of ACC at Ser79 in myotubes exposed to hyperinsulinemia by 
43% (P<0.05, compare bars 2 and 4). Note that data were normalized to 
respective total protein amounts using α-AMPK alpha subunit and α-ACC 
antibodies.  
We next tested the effect of siRNA-mediated knockdown of the catalytic α 
subunits of AMPK on the ability of AICAR and DNP CrPic to modulate GLUT4 
and glucose transport regulation. Since these cells express α1 and α2 isoforms 
of AMPK, oligonucleotides against both were used simultaneously for 
knockdown. The combination of α1 and α2 isoform specific oligonucleotides 
reduced the detectable pan-AMPKα protein by 75% (Fig. 7, P<0.05). Similar to 
non-transfected myotubes, exposure of both siScramble control and siAMPK 
myotubes to hyperinsulinemia significantly impaired insulin-stimulated fold 
increase in PM GLUT4 (Fig. 8A, P<0.05; compare bars 1 and 2, 5 and 6) and 2- 
DG uptake (Fig. 8B, P<0.05; compare bars 1 and 2, 5 and 6). Cr3+ had no
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Figure 7. AMPKα knockdown efficiency.  Following transient siRNA 
transfection of scrambled control oligos (siScramble) or oligos targeting the α 
catalytic subunits of AMPK (siAMPK) as described in Materials and Methods, 
whole-cell lysates were prepared and subjected to Western blot analyses to 
assess pan-AMPKα knockdown efficiency of pan-AMPKα. Immunoblots are 
representative of 4 independent experiments, and all quantitated values 
presented as means ± SEM from 4 independent experiments were determined 
by densitometry and normalized to β-actin. *, P<0.05 vs. respective control.  
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Figure 8. AMPKα is required for Cr3+’s protection against hyperinsulinemia-
induced GLUT4 and glucose transport dysfunction.  Following transient 
siRNA transfection of scrambled control oligos (siScramble) or oligos targeting 
the α catalytic subunits of AMPK (siAMPK) as described in Materials and 
Methods, GLUT4myc and 2-DG transport was analyzed. Cells were pretreated 
as described in Figure 2. After the 16-h and 12-h pretreatments, cells were either 
left untreated or treated with 100 nM insulin for 20 min. The fold increase in 
insulin-stimulated GLUT4myc immunofluorescence was determined (A) or 2-DG 
transport was assessed (B). Mean values ± SEM of GLUT4myc and 2-DG 
transport are shown from 6-8 independent experiments. *, P<0.05 vs. insulin-
stimulated control.    
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significant effect on insulin-stimulated PM GLUT4 (Fig. 8A, compare bars 1 and 
3, 5 and 7) and 2-DG uptake (Fig. 8B, compare bars 1 and 3, 5 and 7) in insulin-
sensitive myotubes. Importantly, CrPic pretreatment of insulin-resistant 
siScramble myotubes protected against GLUT4 (Fig. 8A, compare bars 1 and 4) 
and 2-DG transport dysregulation (Fig. 8B, compare bars 1 and 4); however, the 
beneficial, protective effects of CrPic against GLUT4 (Fig. 8A, P<0.05; compare 
bars 5 and 8) and 2-DG transport dysregulation (Fig. 8B, P<0.05; compare bars 
5 and 8) were not present in siAMPK myotubes. Note we have not measured 
membrane cholesterol or F-actin in these transfected cells based on technical 
difficulties and the high cost associated with these studies, which require a large 
amount of cells for starting material. However, future studies are planned to 
delineate the effects of CrPic on membrane cholesterol and F-actin in both wild-
type and AMPK knockout mice, as described in detail below in the Perspectives 
section.  
In summary, data from the in vitro studies presented in Chapter IIA offer 
several novel observations. First, accompanying the hyperinsulinemia-induced 
decrease in F-actin structure we have previously observed in insulin-resistant L6 
skeletal muscle myotubes (8) is an increase in membrane cholesterol content 
(Fig. 9A). Second, Cr3+ effectively protects against GLUT4 and glucose transport 
dysfunction induced by hyperinsulinemia (Fig. 9B). Third, we provide important 
insight into the mechanism of Cr3+ action by demonstrating that CrPic increases 
phosphorylation/activation of AMPK in both control and insulin-resistant 
myotubes and that AMPK is required for the protective effect of CrPic against
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Figure 9. Model of hyperinsulinemia-induced insulin resistance and 
chromium action in skeletal muscle cells.  Exposure of L6-GLUT4myc 
myotubes to hyperinsulinemia induces insulin resistance. Specifically, exposure 
to hyperinsulinemia results in membrane cholesterol accrual and a reciprocal 
loss of F-actin, which induces GLUT4 and glucose transport dysregulation 
without detectable abnormalities in insulin signaling (A). Pretreatment of L6-
GLUT4myc myotubes with chromium protects against hyperinsulinemia-induced 
insulin resistance. Chromium, via activation of AMPK, prevents hyperinsulinemia-
induced membrane cholesterol accrual, F-actin loss and GLUT4/glucose 
transport dysregulation without enhancing insulin signaling (B).    
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GLUT4/glucose transport dysfunction induced by hyperinsulinemia (Fig. 9B). 
Fourth, the cholesterol-lowering action of CrPic we first reported in control 3T3-
L1 adipocytes (22) effectively lowered the insulin-induced elevation in membrane 
cholesterol to cholesterol levels observed in control, insulin-sensitive myotubes. 
In addition, we provide evidence that membrane cholesterol normalization 
restores F-actin levels and insulin-stimulated GLUT4 translocation to that 
observed in control, insulin-sensitive myotubes independent of insulin signaling 
enhancement (Fig. 9B). In continuation of these studies, we aimed to further 
dissect the mechanism(s) by which the cholesterol-lowering action of AMPK 
positively impacts GLUT4 regulation below in Chapter IIB. 
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II.B. AMPK Enhances Insulin-Stimulated GLUT4 Regulation via Lowering 
Membrane Cholesterol: Evidence for AMPK Activity Countering Membrane 
Cholesterol-Induced Insulin Resistance 
 
II.B.1. Summary 
Studies presented in the previous chapter suggested a novel mechanism of 
AMPK activity that enhances insulin action. Interestingly, it is also known that 
AMPK activity can have insulin-mimetic actions. The studies presented in this 
chapter focused on using well-characterized AMPK activators to further probe the 
cholesterol-lowering mechanism(s) of AMPK activity that impact GLUT4 
regulation. In L6 myotubes stably expressing an exofacial myc-epitope tagged 
GLUT4, AMPK activation by 5-aminoimidazole-4-carboxamide-1-beta-D-
ribonucleoside (AICAR; 45 min, 1 mM) or 2,4-dinitrophenol (DNP; 30 min, 200 
μM) increased surface myc-epitope labeling by ~25%. Insulin stimulation (20 min, 
100 nM) of control cells increased surface GLUT4myc labeling by ~50% and this 
was enhanced by ~25% in the presence of AICAR or DNP pretreatments. 
Consistent with AMPK-mediated suppression of cholesterol synthesis, AICAR 
and DNP decreased membrane cholesterol by ~20%. Surprisingly, whereas 
AMPK knockdown prevented the effect of AICAR and DNP on the increased 
basal and insulin responses, cholesterol add-back only suppressed the AMPK-
associated enhancement in insulin action. Cells cultured in a hyperinsulinemic 
milieu, resembling conditions in vivo that promote the progression/worsening of 
insulin resistance, displayed an increase in membrane cholesterol. This increase 
73 
 
in membrane cholesterol occurred concomitant with a loss of cortical F-actin and 
defects in GLUT4 regulation by insulin. These membrane/cytoskeletal 
derangements as well as GLUT4 dysregulation were prevented by AICAR. Taken 
together, these data suggest that AMPK activity protects against excess 
membrane cholesterol, an underappreciated component of insulin resistance that 
we have found to compromise the normal insulin regulation of GLUT4. 
 
II.B.2. Results 
AMPK activation in L6 myotubes:  Treatment of L6-GLUT4myc myotubes with 
AICAR (1 mM, 45 min) or DNP (200 μM, 30 min) resulted in an increase in AMPK 
Thr172 phosphorylation (Fig. 10A), an event characteristic of increased kinase 
activity. Consistent with this surrogate of increased activity (379); the 
phosphorylation of acetyl CoA carboxylase (ACC) Ser79, a well-characterized 
phosphorylation target of AMPK, was increased by the AICAR and DNP 
treatments (Fig. 10B). Note that the quantification of these analyses represent 
the ratio of immunoblot band intensities detected with anti-phosphorylation 
antibodies [i.e., α-pAMPK, α-pACC] to that measured with specific protein 
antibodies [i.e., α-AMPK, α-ACC]. Finally, in line with AICAR and DNP stimulating 
AMPK Thr172 phosphorylation via an ATP-independent [i.e., AICAR conversion 
to the 5’-AMP analogue ZMP] and an ATP- dependent mechanism [i.e., 
mitochondrial uncoupling that prevents cellular production of ATP], respectively; 
intracellular ATP levels were unchanged by AICAR, yet decreased 40% following 
DNP treatment (Fig. 11). 
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Figure 10. AMPK activation in L6 myotubes. Myotubes were left untreated or 
treated with AICAR (1 mM, 45 min) or DNP (200 μM, 30 min). Total cell extracts 
were prepared and protein concentrations were determined by the Bradford 
method. Equivalent protein amounts were separated by 7.5% SDS/PAGE. The 
resolved fractions were transferred to nitrocellulose, and immunoblot analyses 
were performed using anti-phospho AMPK and anti-pan AMPK (A) and anti-
phospho ACC and anti-pan ACC antibodies (B). Quantification of these analyses 
represent the ratio of immunoblot band intensities detected with anti-
phosphorylation antibodies [i.e., α-pAMPK, α-pACC] to that measured with 
specific protein antibodies [i.e., α-AMPK, α-ACC]. Values are means ±SEM of 6-
12 independent experiments, *P<0.05 vs. control group. 
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Figure 11. AMPK activation by ATP-independent and ATP-dependent 
mechanism. Myotubes were left untreated or treated with AICAR (1 mM, 45 min) 
or DNP (200 µM, 30 min). Intracellular ATP content was measured using a 
luminescence ATP detection assay system as described in Experimental 
Procedures. ATP concentrations were normalized for protein concentration 
determined by the Bradford method. Values are means ±SEM of 4 independent 
experiments. *P<0.05 vs. control group. 
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AMPK signaling enhances basal and insulin-stimulated GLUT4 
translocation:  We next measured cell surface GLUT4 levels under the various 
treatment conditions using the L6-GLUT4myc cell system stably expressing 
GLUT4 tagged with an exofacial myc-epitope (GLUT4myc). In this modified cell 
line the tagged transporter segregates, cycles, and responds to insulin in a 
manner similar to endogenous GLUT4 (431, 436). As shown in Figure 12A 
(panels 1 and 2), acute insulin stimulation of control cells resulted in increased 
immunologic labeling of the myc-epitope at the surface of intact cells. Red 
fluorescent co-staining of nucleic acids with Syto60 was employed as a means to 
normalize the myc signal in quantitative, cell-population based analyses using 
the LI-COR imaging system (Fig. 12A). Acute AICAR and DNP treatments of 
control cells increased surface GLUT4myc labeling (Figs. 12A and 12B, 
compare panels and bars 1, 3, and 5). Furthermore, these treatments resulted in 
an increase in insulin-stimulated PM GLUT4 accumulation (Figs. 12A and 12B, 
compare panels and bars 2, 4, and 6). As documented by others (437), the 
AMPK-stimulated gain of PM GLUT4 in the absence or presence of insulin was 
not associated with phosphorylation/activation of key insulin signaling molecules 
such as the insulin receptor substrate-1 (IRS-1) and Akt-2 (Fig. 13A). In addition, 
an AICAR- or DNP-induced increase in the phosphorylation of AS160 was not 
observed (Fig. 13B, bars 1, 3, and 5), nor did these stimuli affect the insulin-
stimulated phosphorylation of AS160 (Fig. 13B, bars 2, 4, and 6). 
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Figure 12. AMPK activation increases PM GLUT4. Myotubes were left 
untreated or treated with AICAR (1 mM, 45 min) or DNP (200 µM, 30 min) in the 
absence (Basal, panels and bars 1, 3, and 5) or presence (Insulin, panels and 
bars 2, 4, and 6) of acute insulin stimulation (100 nM, 20 min). After treatment, 
cells were fixed and left unpermeabilized. The samples were then labeled with 
anti-myc antibody, washed, and incubated with an infrared-conjugated secondary 
antibody (LiCor) or with FITC-conjugated anti-mouse (confocal). 
Immunofluorescent intensity was normalized to intensity from Syto60, a 
fluorescent nucleic acid stain. Images were collected and quantified with the 
Odyssey system. Representative α-myc immunofluorescent and Syto60 staining 
images of treated myotubes are shown (A). Values are means ±SEM of α-
myc/Syto 60 signal quantification from 20-40 independent experiments (B). 
*P<0.05 vs. control-basal group; #P<0.05 vs. control-insulin group. 
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Figure 13. AMPK activation does not engage or enhance insulin signaling. 
Myotubes were left untreated or treated with AICAR (1 mM, 45 min) or DNP (200 
µM, 30 min) in the absence (Basal, panels and bars 1, 3, and 5) or presence 
(Insulin, panels and bars 2, 4, and 6) of acute insulin stimulation (100 nM, 5 min). 
Total cell extracts were prepared and protein concentrations were determined via 
the Bradford method. Equivalent protein amounts were separated by 7.5% 
SDS/PAGE. The resolved fractions were transferred to nitrocellulose, and 
immunoblot analyses were performed using phospho-IRS-1 and phospho-Akt2 
(A) and phospho-AS160 (B) antibodies. Equal protein loading was confirmed by 
Ponceau staining and by immunoblot analysis with anti-actin antibody. 
Representative immunoblots are shown from 3-6 independent experiments (A). 
Quantification of these analyses represent the ratio of immunoblot band 
intensities detected with anti-phosphorylation antibody [i.e., α-pAS160] to that 
measured with specific protein antibody [i.e., α-AS160]. Values presented in (B) 
are means ±SEM from 6 independent experiments. *P<0.05 vs. control-basal 
group. 
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AICAR- and DNP-treated L6 myotubes display a loss in membrane 
cholesterol:  Concomitant to their effects on GLUT4 trafficking, both AICAR and 
DNP elicited a 20% decrease in membrane cholesterol (Fig. 14A, compare bars 
1-3). As seen in Figure 14B, the AICAR- and DNP-induced loss of membrane 
cholesterol could be prevented with methyl-β-cyclodextrin (βCD) preloaded with 
cholesterol (βCD:Chol). This experimental strategy was found to mitigate AICAR- 
and DNP-enhanced insulin-stimulated GLUT4 translocation (Figs. 14C and 14D, 
compare bars 2, 4, 6, and 8). Interestingly, the insulin-mimetic increase in PM 
GLUT4 induced by AICAR and DNP was not prevented (Figs. 14C and 14D, 
compare bars 1, 3, 5, and 7). Neither basal nor insulin-stimulated PM GLUT4 
levels in control cells were affected by the exogenously added cholesterol (Figs. 
14C and 14D, compare bars 1, 2, 5 and 6). These data suggest that the insulin-
like action of AICAR and DNP on mobilizing GLUT4 to the cell surface results 
from a cholesterol-independent mechanism; whereas membrane cholesterol 
lowering by AICAR and DNP contributes to the enhancement of insulin regulation 
of the transporter. 
 
AMPK mediates cholesterol-dependent and -independent regulation of 
GLUT4:  To further test if increased AMPK activity played a causal role in 
enhancing both basal and insulin-stimulated GLUT4 translocation via PM 
cholesterol regulation, we tested the effect of siRNA-mediated knockdown of the 
catalytic α subunits of AMPK. Since these cells express α1 and α2 isoforms of 
AMPK, oligonucleotides against both were used simultaneously for knockdown.
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Figure 14. AMPK activation decreases membrane cholesterol and AMPK-
enhanced insulin action is cholesterol-dependent. Myotubes were left 
untreated or treated with AICAR (1 mM, 45 min) or DNP (200 µM, 30 min) in the 
absence (A) or presence (B) of exogenous cholesterol (βCD:Chol; 1 mM 8:1 
molar ratio). A plasma membrane-enriched fraction was prepared as described in 
Experimental Procedures. Membrane cholesterol contents (A and B) were 
determined by the Amplex Red cholesterol assay and were normalized to protein 
content as determined by the Bradford method. Basal and insulin-stimulated (100 
nM, 20 min) PM GLUT4 contents (C and D) were determined in myotubes 
treated as described in Figure 12 in the absence or presence of exogenous 
cholesterol (βCD:Chol; 1 mM 8:1 molar ratio, 45 min). Values are means ±SEM 
of 9-13 independent experiments. *P<0.05 vs. control (or control-basal) groups, 
#P<0.05 vs. control-insulin group. 
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The combination of α1 and α2 isoform specific oligonucleotides reduced the 
detectable pan-AMPKα protein by 90% (Fig. 15A). This reduction in AMPKα was 
associated with an ablation of DNP-stimulated membrane cholesterol lowering as 
compared to control cells transfected with scramble oligos (Fig. 15B). In addition, 
consistent with increased AMPK activity regulating basal and insulin-stimulated 
GLUT4 translocation, DNP-stimulated GLUT4 translocation and enhanced insulin 
regulation were both absent in AMPK deficient cells (Fig. 15C). Although we did 
not measure the effect of AICAR on membrane cholesterol in siScramble and 
siAMPK cells, we did observe the same loss of AICAR-stimulated GLUT4 
translocation and enhanced insulin regulation in AMPK deficient cells (Fig. 15D). 
 
AICAR mitigates membrane cholesterol accrual, cortical F-actin loss, and 
GLUT4 dysregulation in hyperinsulinemia-induced insulin-resistant L6 
myotubes:  We next performed membrane cholesterol, cortical F-actin and 
GLUT4 analyses using hyperinsulinemia-induced insulin-resistant L6 myotubes, 
a model system previously observed to have a loss in actin filaments and 
defective GLUT4 regulation by insulin (8). Figure 16A (compare bars 1 and 2) 
shows a small (14%), yet significant increase in membrane cholesterol induced 
by hyperinsulinemia accompanying a 14% loss of cortical F-actin (Fig. 16B, 
compare bars 1 and 2). Consistent with a beneficial effect of AMPK activation on 
insulin responsiveness, AICAR treatment prevented the hyperinsulinemia-
induced membrane cholesterol accrual (Fig. 16A, compare bars 2 and 3) and 
cortical F-actin loss (Fig. 16B, compare bars 2 and 3).   
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Figure 15. AMPK knockdown abrogated DNP-induced membrane 
cholesterol lowering and increased basal- and insulin-stimulated PM 
GLUT4. Myotubes received transient transfections targeting the AMPK α1 and 
α2 catalytic subunits as described in Experimental Procedures. Myotubes were 
then left untreated or treated with AICAR (1 mM, 45 min) or DNP (200 µM, 30 
min). Total cell extracts were prepared from non-transfected control, siScramble-
transfected (siScr), and siAMPKα-transfected myotubes, and SDS-PAGE and 
immunoblot analyses were performed as described in Figure 13 using anti-AMPK 
and anti-actin antibodies (A). Membrane cholesterol content was determined as 
described in Figure 14 (B). Basal and insulin-stimulated (100 nM, 20 min) PM 
GLUT4 contents (C and D) were determined in myotubes treated as described in 
Figure 12. Values are means ±SEM of 6-11 independent experiments. *P<0.05 
vs. siScr (or control-basal) groups, #P<0.05 vs. control-insulin groups. 
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Figure 16. AMPK activation protects against hyperinsulinemia-induced 
membrane cholesterol accrual, F-actin loss, and GLUT4 dysregulation. 
Myotubes were left untreated or treated with AICAR (1 mM, 45 min) in the 
absence or presence of hyperinsulinemia (5 nM, 12 h). Membrane cholesterol 
content was determined as described in Figure 14 (A). Cortical F-actin 
immunofluorescence was performed as described in Experimental Procedures. 
Samples were then labeled with anti-F-actin antibody, washed, and incubated 
with an infrared-conjugated secondary antibody. Immunofluorescent intensity 
was normalized to intensity from Syto60 and quantified with the Odyssey system 
(B). Basal and insulin-stimulated (100 nM, 20 min) PM GLUT4 contents (C) were 
determined in myotubes treated as described in Figure 12. Values are means 
±SEM of 4-8 independent experiments. *P<0.05 vs. control (or control-basal) 
groups; #P<0.05 vs. control-insulin groups. Fold insulin stimulation for each 
treatment condition are presented in panel C inset. 
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These AMPK-induced membrane/cytoskeletal improvements restored regulation 
of GLUT4 by insulin (Fig. 16C, compare bars 4 and 6). Note that the AICAR-
stimulated gain in PM GLUT4 was still observed in cells exposed to 
hyperinsulinemia. Importantly, the AICAR treatment protected against the 
hyperinsulinemia-induced loss of fold insulin stimulation (see Fig. 16C, inset). 
 
Skeletal muscle from insulin-resistant animals display membrane 
cholesterol accrual:  A model whereby membrane cholesterol lowering 
enhances regulation of GLUT4 by insulin suggests that membrane cholesterol 
accrual may contribute to impaired insulin action. Consistent with this model, 
exogenous cholesterol loading has been shown to induce an insulin-resistant 
state in L6 myotubes (10). As a start to translating our cell-based membrane 
cholesterol findings to the whole animal, we extended these analyses to critically 
test whether cholesterol overload contributed to the skeletal muscle cytoskeletal 
abnormalities and insulin resistance. We first evaluated cortical F-actin structure 
in epitrochlearis skeletal muscle, a small flat muscle in the rat forelimb optimal for 
visual inspection, to ensure replication of earlier findings. Results were similar to 
previous observations (8) with the muscles of obese rats showing markedly lower 
F-actin structure (Fig. 17A). Aligned with cholesterol compromising the F-actin 
structure, soleus muscle membrane cholesterol from these same obese rats was 
23% higher (Fig. 17B) than lean controls. Although the epitrochlearis skeletal 
muscle provides a better sample for imaging, we were able to thinly slice an 
imaging sample from the same soleus muscle we used to measure membrane
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Figure 17. Cholesterol Lowering Normalizes Insulin Sensitivity in Obese 
Zucker Skeletal Muscle. Rat epitrochlearis muscle (A) and soleus muscle (B, C, 
D and E) from lean/obese Zucker rats were labeled with antibodies against F-
actin, imaged by confocal microscopy (A and D), and digitally quantitated using 
MetaMorph software (B and E). Remaining soleus muscle was fractionated for 
membrane cholesterol analyses (B) as described in Experimental Procedures. 
Contralateral soleus muscles were subjected to basal and insulin-stimulated 2-
DG uptake measurements (C) as described in Experimental Procedures. 
Subgroups of these muscles were exposed to 2.5 mM βCD for 30 min prior to the 
30 min insulin stimulation. Values are means ±SEM from five independent 
experiments.*, P<0.05 vs. Lean; #, P<0.05 vs. Lean (+Insulin); †, P<0.05 vs. 
Obese (-) βCD.  
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cholesterol before the fractionation procedure. Imaging of those samples 
revealed a reciprocal change in F-actin (Fig. 17B). Insulin-stimulated glucose 
transport measured in contralateral soleus muscle was characteristically lower in 
obese than lean muscle (Fig. 17C, compare bars 2 and 4). When insulin-
resistant muscles were exposed to 2.5 mM βCD and then treated with insulin, 
glucose transport in the obese group was restored to levels that were equal to 
those achieved by the lean group (Fig. 17C, compare bars 4 and 6). Importantly, 
treatment of soleus muscle obtained from the obese group with βCD resulted in a 
gain in F-actin immunofluorescent intensity (Fig. 17, D and E). As muscle 
extracellular [14C] mannitol space was not affected, this βCD-induced cholesterol 
lowering of 25-40% (data not shown) did not compromise membrane integrity, 
results consistent with use of this low-dose βCD reduction of PM cholesterol in 
cell culture (230). 
 In summary, the data presented in Chapter IIB offer several observations that 
extend our understanding of mechanisms of insulin resistance, in particular those 
pertaining to cytoskeletal-based mechanisms (7, 8). First, in support of our 
studies in Chapter IIA, accompanying a hyperinsulinemia-induced decrease in 
cortical F-actin is an increase in membrane cholesterol content (Fig. 18A). 
Second, the cholesterol-lowering ability of increased AMPK activity effectively 
lowered the insulin-induced elevation in membrane cholesterol to cholesterol 
levels observed in control, insulin-sensitive myotubes (Fig. 18B). Third, in line 
with findings in Chapter IIA this membrane cholesterol normalization restored 
cortical F-actin structure and restored insulin-stimulated GLUT4 translocation
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Figure 18. Model of hyperinsulinemia-induced insulin resistance and AMPK 
action in skeletal muscle cells.  Exposure of L6-GLUT4myc myotubes to 
hyperinsulinemia induces insulin resistance. Specifically, exposure to 
hyperinsulinemia results in membrane cholesterol accrual and a reciprocal loss 
of F-actin, which induces GLUT4 and glucose transport dysregulation without 
detectable abnormalities in insulin signaling (A). Treatment of L6-GLUT4myc 
myotubes with AICAR protects against hyperinsulinemia-induced insulin 
resistance. Activation of AMPK with AICAR prevents hyperinsulinemia-induced 
membrane cholesterol accrual, F-actin loss and GLUT4/glucose transport 
dysregulation without enhancing insulin signaling (B).    
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(Fig. 18B). Furthermore, testing whether these cell culture-based findings 
translate to the whole animal revealed strikingly similar and correctable 
membrane/cytoskeletal abnormalities in isolated skeletal muscle, a tissue 
responsible for approximately 80% of postprandial glucose disposal (29) and 
regarded as a major peripheral site of insulin resistance in T2D (28). To further 
translate our in vitro findings to an animal model of insulin resistance, the 
following studies in Chapter IIC were performed to determine the effects of CrPic 
supplementation in vivo on skeletal muscle AMPK activity and 
membrane/cytoskeletal parameters of insulin sensitivity. 
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II.C. Chromium Improves Skeletal Muscle Membrane/Cytoskeletal 
Parameters and Insulin Sensitivity in High-Fat Fed C57Bl/6J Mice 
 
 II.C.1. Summary 
To next test Cr3+ action in vivo, we utilized obesity-prone C57Bl/6J mice fed 
either a low fat (LF) or high fat (HF) diet for eight weeks without or with CrPic 
supplementation administered in the drinking water (8 µg/kg/day) beginning five 
weeks before dietary intervention. HF feeding increased body weight beginning 
four weeks post-diet intervention regardless of CrPic supplementation and was 
independent of changes in food consumption. HF feeding for eight weeks 
induced glucose intolerance and insulin resistance. As observed in other animal 
models, isolated muscles from HF-fed mice displayed membrane cholesterol 
accrual and loss of F-actin. Early CrPic supplementation protected against 
glucose intolerance and insulin resistance in HF-fed mice. CrPic supplementation 
also protected against skeletal muscle membrane cholesterol accrual, F-actin 
loss and selectively increased AMPK activation in HF-fed mice. Together these 
data identify a mechanism by which Cr3+ may positively impact glycemic status, 
thereby stressing a beneficial action of this micronutrient in glucose homeostasis.  
 
 II.C.2. Results 
 In vivo CrPic supplementation study design: To begin translating our in 
vitro findings to an animal model of insulin resistance and test Cr3+ action in vivo, 
we utilized the obesity-prone C57Bl/6J mice fed either a LF or HF diet. 
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Development of obesity and insulin resistance as a result of excessive dietary fat 
is frequently studied in this model (438-441), which is considered to be 
representative of diet-induced obesity and insulin resistance in humans 
compared to other genetically-modified diabetic animal models. Studies have 
utilized these mice to test how excess dietary fat affects the physiology of liver, 
muscle and fat metabolism (442-444). Based on the fact commercial Cr3+-
containing nutritional supplements generally contain 200 to 600 µg Cr3+ and an 
average human body mass of 70 kg, the supplements provide ~3 to 9 µg Cr3+/kg 
body weight/day. In these studies we administered 8 µg Cr3+/kg body weight/day 
(CrPic) dissolved in the drinking water to LF and HF-fed C57Bl/6J mice beginning 
during the acclimation period (-5 to 0 weeks). The mice in this study were fed ad 
libitum NIH standard chow and water for two weeks, acclimated to the LF diet for 
three additional weeks to allow acclimation to the increased palm oil content in 
the diet and then divided into treatment groups (Fig. 19). At week 0, mice in this 
dietary intervention study were randomly divided into one of four groups: LF (-) 
CrPic, HF (-) CrPic, LF (+) CrPic and HF (+) CrPic. Control (LF) mice received a 
diet containing 20% kcal from protein, 70% kcal from carbohydrates and 10% 
kcal from fat. HF-fed mice received a diet containing 20% kcal from protein, 35% 
kcal from carbohydrates and 45% kcal from fat. These diets were modified with 
adaptations regarding type of fat (palm oil instead of lard) and carbohydrates to 
better mimic the FA/carbohydrate composition of the average human diet in 
Western societies and have been shown to induce significant insulin resistance 
in C57Bl/6J mice (445). The modified HF diet mimics the ratio of saturated to
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Figure 19. Early CrPic supplementation and eight week diet intervention 
study design. C57Bl/6J mice were acclimated for 5 weeks with or without CrPic 
supplementation. Mice were fed ad libitum NIH standard chow and water for two 
weeks, acclimated to the LF diet for three additional weeks and then divided into 
treatment groups. At 0 weeks, mice were either LF- or HF-fed ± continued CrPic 
supplementation. All procedures and ex vivo tissue analyses were performed 
after eight weeks of dietary intervention.   
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monounsaturated to polyunsaturated FAs (40:40:20). In addition, these diets 
were made with a Cr3+-free mineral mix (S17902) and Avicel PH101 (instead of 
cellulose, which contains Cr3+). By addition of chromium potassium sulfate, to the 
Cr3+-free diets, both the LF and HF test diets were controlled to contain an equal 
amount of this micronutrient. Note the energy density of all nutrients, except fat 
and starch, is equal. Body weights, food consumption and water consumption 
were measured once per week. All other procedures and analyses outlined 
below were performed after eight weeks of dietary intervention to determine the 
effects of early CrPic supplementation on whole body glucose tolerance and 
membrane/cytoskeletal parameters of insulin sensitivity in skeletal muscle. We 
primarily focused on skeletal muscle in these studies since skeletal muscle is 
responsible for a large majority of postprandial glucose disposal (29) and 
represents a major site of insulin resistance (28). Therefore, we performed this 
series of experiments to deepen our insight into the effects of Cr3+ in this 
significant tissue during the development of insulin resistance. 
 
HF feeding increases body weight independently of changes in food 
consumption and/or CrPic supplementation: Body weight was measured 
once per week during the acclimation and dietary intervention period. As shown 
in Figure 20, HF feeding significantly increased body weight in C57Bl/6J mice 
compared to LF feeding beginning four weeks after dietary intervention. CrPic 
supplementation had no significant effect on body weight in C57Bl/6J mice fed 
either the LF or HF diet (Fig. 20). The observed changes in body weight were
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Figure 20. HF feeding increases body weight and is not affected by CrPic 
supplementation. C57Bl/6J mice were acclimated for 5 weeks with (blue) or 
without (black) CrPic supplementation. At 0 weeks, mice were LF- (square) or 
HF- (circle) fed ± continued CrPic supplementation. Body weight was measured 
once per week throughout the acclimation period and dietary intervention. Body 
weight values are means ± SEM from 12 mice per group. *, P<0.05 vs. LF (-/+) 
CrPic; **, P<0.01 vs. LF (-/+) CrPic; ***, P<0.001 vs. LF (-/+ CrPic). 
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independent of changes in food consumption (i.e. neither HF feeding nor CrPic 
supplementation had a significant effect on food consumption at any point during 
the dietary intervention) (Fig. 21). Water consumption was measured once per 
week during the acclimation period and dietary interventions. Water consumption 
averaged between 2.6-2.7 ml/day in CrPic-supplemented mice (Fig. 22) similar 
to levels observed in previous pilot studies. In pilot studies we determined that 
these water consumption values equate to approximately 8 µg/kg/day CrPic 
intake, very close to our target amount. For a 70 kg human, this intake equates to 
~600 µg/day within the 200-600 µg dose range found in Cr3+ supplements. 
 
HF feeding induces glucose intolerance, and CrPic supplementation 
improves glucose tolerance and insulin sensitivity in HF-fed C57Bl/6J mice: 
To characterize the effects of HF feeding and CrPic supplementation on whole 
body glucose tolerance and insulin sensitivity, we performed intraperitoneal 
glucose and insulin tolerance tests following eight weeks of dietary intervention. 
C57Bl/6J mice were fasted for six hours (from 8:00 a.m. to 2:00 p.m.) in these 
studies. In our intraperitoneal glucose tolerance tests (IPGTTs), we injected the 
mice with 2 g D-glucose/kg body weight (individually-dosed) at time 0 and 
measured blood glucose via tail blood collection at 15 min, 30 min, 60 min, 90 
min and 120 min post-injection to monitor response to the glucose challenge. As 
shown in Figure 23A, HF feeding induced glucose intolerance compared to LF (-
/+ CrPic) mice. Area under the curve (AUC) analyses revealed a 54% (P<0.001) 
increase in HF-fed AUC compared to LF-fed (Fig. 23B, compare bars 1 and 3).
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Figure 21. HF feeding and CrPic supplementation do not affect food 
consumption. Food consumption was measured once per week following 
dietary intervention for eight weeks. Weekly food consumption values were 
divided by the number of days between each food consumption determination to 
obtain average food consumption per day values. Food consumption values are 
means ± SEM from 12 mice per group.   
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Figure 22. HF feeding and CrPic supplementation do not affect water 
consumption. Water consumption was measured once per week throughout the 
5-week acclimation period and 8-week dietary intervention period. Weekly water 
consumption values were divided by the number of days between each water 
consumption determination to obtain average water consumption per day values. 
While HF feeding and CrPic did not affect water consumption throughout most of 
the study, we observed statistical differences in the LF (+) CrPic group at 6 
weeks post-dietary intervention and the LF (-) CrPic group at 7 weeks post-
dietary intervention. Water consumption values are means ± SEM from 10-12 
mice per group. *, P<0.05 vs. all other groups.   
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Figure 23. HF feeding for eight weeks induces glucose intolerance, and 
early CrPic supplementation improves glucose tolerance in HF-fed mice. 
Intraperitoneal glucose tolerance tests (IPGTT) were performed following eight 
weeks of dietary intervention. C57Bl/6J mice were fasted for six hours (from 8:00 
a.m. to 2:00 p.m.) in all IPGTT studies. Mice were injected with 2 g/kg D-glucose 
(individually-dosed) at time 0 and blood was obtained for blood glucose analysis 
via tail blood collection at 15 min, 30 min, 60 min, 90 min and 120 min post-
injection. Blood glucose values (A) and AUC values (B) are means ± SEM from 
5-6 mice per group. *, P<0.05 vs. LF (-/+) CrPic; **, P<0.01 vs. LF (-/+) CrPic;  
***, P<0.001 vs. LF (-/+ CrPic); #, P<0.05 vs. HF (-) CrPic.   
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CrPic supplementation in LF-fed mice had no significant effect on glucose 
tolerance (Fig. 23A) as determined by AUC analysis (Fig. 23B, compare bars 1 
and 2). In line with Cr3+ action being dependent on the diabetic milieu, CrPic 
supplementation significantly improved glucose tolerance in HF-fed mice 
compared to non-supplemented HF-fed mice (Fig. 23A) as evidenced by a 15% 
reduction (P<0.05) in IPGTT AUC (Fig. 23B, compare bars 3 and 4). However, 
CrPic supplementation did not completely restore glucose tolerance to levels 
observed in LF (-) CrPic mice (Fig. 23B, compare bars 1 and 4).  
 To complement our IPGTT analyses, we performed intraperitoneal insulin 
tolerance tests (IPITTs) following eight weeks of dietary intervention (Fig. 24A). 
C57Bl/6J mice were fasted for six hours (from 8:00 a.m. to 2:00 p.m.) before 
injection of insulin. In our IPITTs, we injected the mice with 1.0 unit of insulin per 
kg body weight (individually-dosed) at time 0 and measured blood glucose via tail 
blood collection at 15 min, 30 min, 60 min, 90 min and 120 min post-injection to 
observe the response of each mouse to an insulin challenge. In line with IPGTTs, 
HF feeding reduced insulin sensitivity (i.e. 24% decrease in AUC; P<0.05) eight 
weeks after dietary intervention (Fig. 24B, compare bars 1 and 3). CrPic had no 
effect on insulin sensitivity in LF-fed mice (Fig. 24B, compare bars 1 and 2); 
however, CrPic supplementation in HF-fed mice improved insulin sensitivity (Fig. 
24B, P<0.05; compare bars 3 and 4). Together these data strongly suggest an 
improvement in both glucose intolerance and insulin sensitivity in CrPic-
supplemented HF-fed mice compared to non-supplemented HF-fed mice.    
 To complement our IPGTT and IPITT procedures, blood was collected in the
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Figure 24. HF feeding for eight weeks induces insulin resistance, and early 
CrPic supplementation improves insulin sensitivity in HF-fed mice. 
Intraperitoneal insulin tolerance tests (IPITT) were performed following 8 weeks 
of dietary intervention. C57Bl/6J mice were fasted for 6 hours (from 8:00 a.m. to 
2:00 p.m.) in all IPITT studies. Mice were injected with 1.0 unit of insulin per kg 
body weight (individually-dosed) at time 0 and blood was obtained for blood 
glucose analysis via tail blood collection at 15 min, 30 min, 60 min, 90 min and 
120 min post-injection. Blood glucose values (A) and AUC values (B) are means 
± SEM from 4-6 mice per group. For AUC analyses, the axis was set at 100; 
therefore, the area above the curve was determined for IPITTs as opposed to 
area under the curve for IPGTT analyses. *, P<0.05 vs. LF (-/+) CrPic; **, P<0.01 
vs. LF (-) CrPic; #, P<0.05 vs. HF (-) CrPic.    
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prandial state after eight weeks of dietary/Cr3+ intervention to determine the 
effects of the HF diet and CrPic supplementation on plasma insulin levels to 
monitor insulin sensitivity. Plasma was obtained by centrifugation, and plasma 
insulin concentrations were determined using an Ultra Sensitive Mouse ELISA 
kit. Plasma insulin concentration strongly trended to be increased (75%) in the 
HF-fed (-) CrPic group compared to LF-fed mice (-/+ CrPic) (Fig. 25, compare 
bars 1, 2 and 3). Importantly, plasma insulin concentrations in CrPic-
supplemented HF-fed mice were not as elevated (17%) compared to non-
supplemented HF-fed mice (Fig. 25, compare bars 2 and 4).   
 
CrPic supplementation protects against HF diet-induced skeletal muscle 
membrane/cytoskeletal derangements in C57Bl/6J mice: To determine if the 
effects of CrPic on membrane/cytoskeletal parameters in insulin-resistant 
skeletal muscle myotubes translate to our animal model of insulin resistance, 
isolated skeletal muscles from C57Bl/6J mice were analyzed following eight 
weeks of dietary intervention. To measure membrane cholesterol, mixed hindlimb 
muscles were dissected in the prandial state and homogenized. Membrane 
fractions were prepared as described in Experimental Procedures, and 
cholesterol content was determined using the Amplex Red cholesterol assay and 
normalized to protein levels. As observed in vitro using hyperinsulinemia-induced 
insulin resistance, HF feeding significantly increased membrane cholesterol 
content (15%, P<0.05) compared to the LF-fed (-) CrPic group (Fig. 26, compare 
bars 1 and 2). In support of a cholesterol-based mechanism of Cr3+ action in
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Figure 25. CrPic supplementation protects against the HF diet-induced 
increase in plasma insulin. Blood was obtained from C57Bl/6J mice in the 
prandial state following eight weeks of dietary intervention by cardiac puncture. 
Plasma was obtained by centrifuging blood samples for at 4°C for 15 min at 2000 
rpm. Plasma insulin levels were determined using an Ultra Sensitive Mouse 
Insulin ELISA kit. White bars and black bars represent LF and HF-fed groups, 
respectively. Insulin values are means ± SEM from 6 mice per treatment group. 
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Figure 26. CrPic supplementation protects against HF diet-induced 
membrane cholesterol accrual in skeletal muscle. Mixed hindlimb muscles 
were dissected from C57Bl/6J mice in the prandial state following eight weeks of 
dietary intervention. A plasma membrane-enriched fraction was prepared as 
described in Experimental Procedures. Membrane cholesterol contents were 
determined by the Amplex Red cholesterol assay and were normalized to protein 
content as determined by the Bradford method. White bars and black bars 
represent LF and HF-fed groups, respectively. Values are means ±SEM of 5-6 
muscles per treatment group. *, P<0.05 vs. Low Fat (-) CrPic. 
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skeletal muscle, CrPic supplementation significantly decreased membrane 
cholesterol content in LF-fed mice (14%, P<0.05) (Fig. 26, compare bars 1 and 
3), as well as in HF-fed mice (22%, P<0.05) (Fig. 26, compare bars 1 and 4).  
 To analyze F-actin integrity in skeletal muscle, we isolated soleus muscles in 
the prandial state. Following fixation and permeabilization, soleus muscles were 
labeled with an F-actin antibody and imaged by confocal microscopy. Cortical F-
actin labeling of individual muscle fibers were analyzed using Metamorph 
software. In line with increased membrane cholesterol disrupting cortical F-actin 
structure in the HF-fed mice, we observed a reciprocal decrease (21%, P<0.05) 
in F-actin signal in HF-fed mice compared to LF-fed (-) CrPic mice (Fig. 27, 
compare bars/images 1 and 2). CrPic supplementation in LF-fed mice 
significantly increased (19%, P<0.05) skeletal muscle F-actin signal (Fig. 27, 
compare bars/images 1 and 3). This increase in F-actin is accompanied by a 
decrease in membrane cholesterol, as described above (Fig. 26, compare bars 1 
and 3). Strikingly, CrPic supplementation in HF-fed mice restored the F-actin 
signal to a similar level as LF-fed (-) CrPic mice (Fig. 27, compare bars 1 and 4). 
  
CrPic supplementation increases skeletal muscle AMPK activation in HF-
fed mice: Based on the role of AMPK in Cr3+ action we observed in vitro, we 
isolated skeletal muscles to analyze AMPK activation and downstream signaling 
to ACC and HMGR. Gastrocnemius muscles were isolated in the prandial state 
following 8 weeks of dietary intervention. Muscles were freeze-clamped 
immediately following dissection in an effort to preserve AMPK activation. Whole-
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Figure 27. CrPic supplementation protects against HF diet-induced F-actin 
loss in skeletal muscle. Soleus muscles were dissected from C57Bl/6J mice in 
the prandial state following eight weeks of dietary intervention. Following fixation 
and permeabilization, muscles were labeled with antibodies against F-actin, 
imaged by confocal microscopy, and digitally quantitated using MetaMorph 
software. White bars and black bars represent LF and HF-fed groups, 
respectively. F-actin intensities from isolated soleus muscles are means ± SEM 
from 3-6 muscles (20-40 fibers) analyzed per treatment group, and 
representative muscle fibers are shown below respective treatment groups. *, 
P<0.05 vs. Low Fat (-) CrPic. 
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cell lysates were prepared and subjected to Western blot analyses to assess 
AMPK Thr172 phosphorylation, ACC Ser79 phosphorylation and HMGR Ser872 
phosphorylation. As observed in vitro following CrPic treatment of skeletal 
muscle myotubes, CrPic supplementation selectively increased phosphorylation 
of AMPK Thr172 in muscles from HF-fed mice (45%, P<0.05), with no effect 
observed in muscles obtained from LF-mice (Fig. 28A). To confirm that this 
increase in phosphorylation was associated with an increase in AMPK activity, 
we analyzed downstream AMPK signaling to ACC and HMGR. CrPic 
supplementation robustly increased downstream phosphorylation of ACC Ser79 
in muscles from HF-fed mice (99%, P<0.05) (Fig. 28B) in line with a selective 
increase in AMPK activity in the insulin-resistant myotubes and skeletal muscle. 
Finally, we analyzed HMGR phosphorylation at Ser872, which is a known 
downstream target of AMPK that inactivates HMGR. These analyses were based 
on the observed effects of Cr3+ on cellular cholesterol levels, as HMGR is the 
rate-limiting enzyme in cholesterol synthesis. Preliminary analyses suggests that 
phosphorylation at HMGR Ser872 is increased by CrPic supplementation in HF-
fed mice (Fig. 28C), further supporting a role for AMPK in Cr3+’s modulation of 
membrane cholesterol content and F-actin integrity in insulin-resistant skeletal 
muscle.    
Taken together, these in vivo findings are consistent with early CrPic 
supplementation improving glucose tolerance and insulin sensitivity in C57Bl/6J 
mice fed a HF diet for eight weeks. In summary, the beneficial effects of Cr3+ in 
this study on whole body glucose tolerance and insulin sensitivity were
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Figure 28. CrPic supplementation increases skeletal muscle AMPK 
activation in HF-fed mice. Mixed hindlimb muscles were dissected from 
C57Bl/6J mice in the prandial state following eight weeks of dietary intervention 
and snap-frozen in liquid nitrogen. Whole-cell lysates were prepared and 
subjected to Western blot analyses to assess AMPK(Thr172) phosphorylation 
(A), ACC(Ser79) phosphorylation (B) and HMGR(Ser872) phosphorylation (C). 
White bars and black bars represent LF and HF-fed groups, respectively. 
Immunoblots shown in A, B and C are representative of 5-11 mice per treatment 
group. All quantitated values shown in A and B are presented as means ± SEM 
from 5-11 mice and were determined by densitometry and normalized to total 
protein (AMPK and ACC, respectively). *, P<0.05 vs. Low Fat (-) CrPic.   
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independent of changes in food intake and/or body weight. Mechanistically, we 
observed membrane cholesterol and F-actin loss induced by the HF feeding (Fig. 
29A) similarly to studies from our group in other animal models of insulin 
resistance (8, 10). The levels of hyperinsulinemia and glucose intolerance we 
observed in HF-fed mice, indicative of insulin resistance, were not observed in 
HF-fed mice supplemented with CrPic in the drinking water for the acclimation 
period and eight week diet intervention (Fig. 29B). Consistent with the idea that 
Cr3+ has no beneficial effect on glucose metabolism in lean, healthy animals, we 
did not observe an effect of CrPic supplementation on glycemic status in the LF-
fed mice. Importantly, CrPic supplementation protected against membrane 
cholesterol accrual and F-actin loss in skeletal muscles obtained from HF-fed 
mice similarly to the effects of CrPic treatment in skeletal muscle myotubes in 
vitro that have been shown to positively impact insulin sensitivity (Fig. 29B). Our 
isolated skeletal muscle analyses support a mechanism of Cr3+ action similar to 
what we observe in cell culture model systems. We determined that CrPic 
supplementation selectively increased AMPK activation in HF-fed mice (Fig. 
29B), consistent with CrPic activating AMPK more robustly in insulin-resistant 
myotubes in our in vitro studies. In conclusion, our in vitro data presented in 
Chapter IIA and IIB and in vivo data presented in Chapter IIC suggest that AMPK 
activation by CrPic may mediate the beneficial effects of CrPic on 
membrane/cytoskeletal parameters of insulin sensitivity. Furthermore, these data 
provide novel mechanistic insight into the mechanisms by which Cr3+ and AMPK 
activation benefit GLUT4 regulation and glucose/lipid homeostasis. 
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Figure 29. Model of high-fat diet-induced insulin resistance and effects of 
CrPic supplementation in C57Bl/6J skeletal muscle. HF feeding for 8 weeks 
induces glucose intolerance and insulin resistance in C57Bl/6J mice. Specifically, 
HF feeding results in skeletal muscle membrane cholesterol accrual and a 
reciprocal loss in F-actin loss, which is accompanied by whole body glucose 
intolerance and reduced insulin sensitivity (A). Early CrPic supplementation in 
HF-fed mice during the 5-week acclimation period and during the 8-week feeding 
period improves glucose tolerance and insulin sensitivity. CrPic supplementation 
in HF-fed mice also increases activation of AMPK and protects against 
membrane cholesterol accrual and F-actin loss in isolated skeletal muscles (B).   
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Chapter III.  Perspectives 
The findings presented above in Chapter II have provided insight into the 
mechanisms by which Cr3+ affects membrane/cytoskeletal aspects of insulin 
sensitivity in skeletal muscle. The following section considers future research 
questions stemming from the current research and puts these findings into 
perspective regarding the fundamental findings in the field described in the 
introduction above. As previously discussed in detail, the importance of key distal 
GLUT4 regulatory events beyond the insulin signaling cascade have been 
demonstrated by multiple groups (reviewed in (17)). It is appreciated that states 
of insulin resistance involve defects in distal GLUT4 regulatory parameters while 
insulin signaling remains intact (7, 8, 22).  Findings from the present studies 
further add to this concept by highlighting reversible distal derangements in the 
PM and cortical actin cytoskeleton that occur in both a hyperinsulinemia-induced 
insulin-resistant cell culture model and HF-fed mouse model.     
To dissect the cholesterol-based mechanism(s) of Cr3+ action and determine 
the role of the AMPK-HMGR signaling axis in the studies in Chapter IIA, we first 
utilized the HMGR inhibitor atorvastatin. We performed pilot studies using 
atorvastatin (ATV); however, we observed that ATV increased AMPK Thr172 
phosphorylation independent of its inhibition of HMGR, consistent with previous 
reports (433). Since this off-target effect of ATV on AMPK complicated our data 
interpretation, we next tried to identify another method of inhibiting cholesterol 
synthesis without increasing AMPK activation. We tested the squalene synthase 
inhibitor, zaragozic acid A (ZA), which inhibits cholesterol synthesis downstream 
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of HMGR (432). This inhibitor has been utilized to decrease cholesterol content 
primarily in cultured neurons (446, 447) and has been shown to have no 
detrimental effect on cell viability in rat and human myotubes at the dose (10 µM) 
we used in these studies (448). We did not observe increased AMPK Thr172 
phosphorylation using this method of cholesterol synthesis inhibition, and ZA 
effectively recapitulated the protective effects of CrPic against hyperinsulinemia-
induced membrane/cytoskeletal derangements and insulin resistance. 
Importantly, this data suggests that F-actin integrity is regulated by membrane 
cholesterol levels, as evidenced by the observation that inhibition of cholesterol 
synthesis by ZA protected against F-actin dysregulation induced by 
hyperinsulinemia. The observed effects of ZA on membrane/cytoskeletal aspects 
of GLUT4 regulation suggest interplay between the PM lipid environment and 
cortical F-actin cytoskeleton and warrant further mechanistic studies to determine 
the cholesterol-dependent mechanisms underlying the cytoskeletal-based 
actions of Cr3+.  
Our studies utilizing siRNA-targeted knockdown of AMPK catalytic activity are 
consistent with AMPK mediating the protective effect of Cr3+ against 
GLUT4/glucose transport dysregulation induced by hyperinsulinemia. Findings 
from AMPK knockdown experiments revealed that the antidiabetic actions of 
CrPic are absent in cells with diminished AMPKα protein. A recent report utilizing 
pharmacological inhibition of AMPK by compound C has also demonstrated a 
causal role for AMPK in Cr3+’s inhibition of the secretion of an adipokine 
implicated in insulin resistance, resistin, in insulin-resistant 3T3-L1 adipocytes 
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(311). Together these studies begin to establish beneficial roles for AMPK in Cr3+ 
action in the context of insulin resistance. While our findings suggest that AMPK 
mediates CrPic action in our cell system, it is possible that CrPic action relies on 
a potential upstream and/or downstream signaling event in the AMPK signaling 
pathway. Further dissection of the involvement of proximal and distal signaling 
events is currently underway to determine the role(s) of AMPK activation in Cr3+ 
action. The studies in Chapter IIA implicate HMGR, and subsequent regulation of 
cholesterol synthesis, as an important aspect of how CrPic positively impacts 
GLUT4 regulation. However, other mechanisms downstream of AMPK such as 
interactions with the HBP, potentially through inhibition of GFAT (449), may also 
be involved. As HBP activation has been demonstrated by our group to be 
increased in L6 myotubes exposed to palmitate (10) and 3T3-L1 adipocytes 
exposed to hyperinsulinemia (11), this also represents a potential node of 
cholesterol synthesis regulation impacted by Cr3+ action.      
Interestingly, recent data suggest that the antidiabetic drug metformin 
enhances insulin action by increasing membrane fluidity (307, 308). As we have 
observed after CrPic treatment, metformin has also been reported to increase 
GLUT4 translocation to the PM (309, 310, 450-453). It has also been observed 
that the relative enhancing effect of metformin is higher in 3T3-L1 adipocytes 
incubated in 25 mM glucose rather than in 5 mM glucose, consistent with its 
selective action in hyperglycemic conditions in vivo (454). We have observed that 
the relative enhancing effect of CrPic on GLUT4 translocation is also higher in 
adipocytes incubated in 25 mM glucose rather than 5 mM glucose (23). An 
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increase in PM cholesterol was noted in the cells cultured in 25 mM glucose, and 
the beneficial action of CrPic was attributed to lowering PM cholesterol content to 
that measured in control, 5 mM glucose, insulin-sensitive cells (23). As reported 
for metformin (455-458), the effects of CrPic are not attributed to increased 
expression of GLUT4 protein but rather its translocation and/or activation state 
(262, 459, 460). In line with these observations, our studies herein support a 
shared mechanism for the beneficial effects of metformin and CrPic on cellular 
insulin sensitivity, with AMPK activation and the regulation of PM cholesterol 
being a central component of this mechanism. 
The data presented in Chapter IIA suggest that AMPK activation is an 
important aspect of the mechanism of action of Cr3+ in insulin-resistant skeletal 
muscle cells. Furthermore, this study demonstrates that PM cholesterol 
influences cytoskeletal structure essential for insulin-regulated GLUT4 
translocation and glucose transport. Although intermittent study has coupled 
membrane fluidity to insulin sensitivity (228, 306, 461), a mechanistic 
understanding has remained elusive. It is an interesting thought that PM 
cholesterol lowering may be a common and key action of CrPic and metformin, 
as well as several other antidiabetic agents known to display AMPK-stimulating 
and cholesterol-lowering properties (e.g., berberine (342, 462-464), 
cryptotanshinone (465) and fibrates (466, 467)). Further in vivo studies in 
Chapter IIC discussed below were performed to characterize the effects of CrPic 
supplementation on glucose metabolism and skeletal muscle 
membrane/cytoskeletal parameters of insulin sensitivity in an animal model of 
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insulin resistance. Because cortical F-actin integrity is required for proper GLUT4 
regulation by insulin, we hypothesized that the protective effects of CrPic against 
membrane/cytoskeletal derangements associated with insulin resistance and 
activation of AMPK observed in vitro to translate to an improvement in skeletal 
muscle insulin sensitivity in vivo.    
The studies presented in Chapter IIB were performed in direct collaboration 
with and in continuation of studies performed by a fellow graduate student in our 
laboratory, Kirk Habegger. In Chapter IIB studies we examined in vitro effects of 
increased AMPK activity on membrane cholesterol and GLUT4 regulation in L6 
myotubes. Our group has previously reported that experimental lowering of 
membrane cholesterol (i.e., with sphingomyelinase or cholesterol binding agents 
such as βCD, nystatin and filipin increased GLUT4 exocytosis in 3T3-L1 
adipocytes (230)). We also found a mechanistic aspect of the antidiabetic activity 
of Cr3+ appeared to entail membrane cholesterol lowering (22, 23). In addition, 
we observed that AMPK activity was increased in cells treated with Cr3+. These 
later results led us to speculate that increased AMPK activity may lower 
membrane cholesterol in insulin resistant cells, which could reverse a portion of 
the defects in insulin-regulated GLUT4 trafficking. 
 Therefore, in Chapter IIB we tested if stimulation of AMPK with AICAR or 
DNP affected membrane cholesterol and whether membrane cholesterol accrual 
explained, at least in part, defects in GLUT4 regulation in insulin-resistant cell 
and animal models. Consistent with increased AMPK activity lowering membrane 
cholesterol, we found both AICAR and DNP lowered membrane cholesterol. 
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Moreover, the effect of these agents on enhancing insulin-stimulated GLUT4 
translocation was eliminated by adding back exogenous cholesterol. Intriguingly, 
cholesterol add-back did not suppress the insulin mimetic action of AICAR or 
DNP; whereas siAMPK knockdown did, suggesting AMPK regulates basal and 
insulin-stimulated GLUT4 by divergent mechanisms. Although in the present 
study we attempted to delineate this further, which we provide expanded 
information on below, an important preliminary question we asked was if 
membrane cholesterol accrual could represent an unappreciated aspect of 
insulin resistance and whether AMPK stimulation countered membrane 
cholesterol toxicity. 
 Based on additional tests we conducted, we were surprised that the insulin 
mimetic AICAR- and DNP-stimulated GLUT4 translocation was independent of 
membrane cholesterol lowering. For example, as we depict in Figure 30, if 
AMPK activity regulates basal GLUT4 translocation by a cholesterol-independent 
mechanism; whereas AMPK enhances insulin-stimulated GLUT4 translocation 
via lowering membrane cholesterol, a prediction would be lowering membrane 
cholesterol with βCD would only affect insulin-stimulated, not basal, GLUT4 
translocation. Contrary to this prediction, we found that βCD increased both basal 
and insulin-stimulated GLUT4 translocation in L6 myotubes (Fig. 30B). One 
possible explanation for this observation could be that the βCD-induced 34% loss 
of membrane cholesterol (Fig. 30B, inset) that was more than that induced by 
AMPK activation (i.e., 19.8% and 24.1% for AICAR and DNP, respectively)
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Figure 30. Proposed model of divergent membrane cholesterol-
independent and dependent AMPK pathways regulating basal and insulin-
stimulated PM GLUT4 content. Proposed model of divergent AMPK pathways 
highlighting that the insulin-like action of AICAR and DNP on mobilizing GLUT4 
to the cell surface results from a cholesterol-independent mechanism; whereas 
membrane cholesterol lowering by AICAR and DNP contributes to the 
enhancement of insulin regulation of the transporter (A). Basal and insulin-
stimulated (100 nM, 20 min) PM GLUT4 contents (B) were determined in 
myotubes treated as previously described in the absence or presence of βCD 
(2.5 mM, 30 min). Membrane cholesterol contents (panel B inset) were 
determined as previously described. Myotubes were left untreated or treated with 
AICAR (1 mM, 45 min), DNP (200 μM, 30 min), βCD (2.5 mM, 30 min), or 
βCD:Chol (1 mM 8:1 molar ratio, 45 min). Cell lysates were subjected to 
SDS/PAGE and immunoblot analyses using anti-phospho AMPK and anti-pan 
AMPK antibodies (C). Representative immunoblots are shown from 3 
independent experiments. Values are means ±SE of 4-5 independent 
experiments. *, P<0.05 vs. control (or control-basal) groups; #, P<0.05 vs. 
control-insulin group. 
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impaired the endocytic retrieval of cell surface GLUT4, as we and others have 
found occurs with greater reduction of membrane cholesterol (229, 230). Another 
possible explanation could be that βCD and/or βCD:Chol may have an “off-
target” effect on AMPK activity. For example, if βCD increased AMPK activity 
then a predicted outcome would be a gain in both basal and insulin-stimulated 
GLUT4 translocation with the use of βCD and βCD:Chol. However, we did not 
detect an increase in AMPK Thr172 phosphorylation with either βCD or 
βCD:Chol (Fig. 30C). In this context, the specific inhibition of enhanced insulin-
stimulated, not basal, GLUT4 translocation with βCD:Chol seems to implicate 
membrane cholesterol lowering as a mechanism by which AMPK enhances 
insulin action, but not basal GLUT4 regulation. We currently hold, and will 
continue to test the idea, that a divergent AMPK-mediated, cholesterol-
independent pathway can regulate basal GLUT4 levels. As previously 
mentioned, although we considered employing statins to inhibit cholesterol 
synthesis to avoid the complexities of βCD, multiple reports and our own findings 
showing increased AMPK activity in cells treated with statins also render their 
use as a tool in testing this model ineffective (433, 468). 
Regardless of whether or not divergent pathways mediate the action of AMPK 
on basal and insulin-stimulated GLUT4, our data suggest a novel mechanism of 
AMPK action. Whether membrane cholesterol toxicity is a component of insulin 
resistance certainly requires further testing; however, this study found membrane 
cholesterol accrual in two well-described in vitro and in vivo models of insulin 
resistance. Furthermore, these data support the concept that the accumulation of 
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membrane cholesterol compromises cortical F-actin structure, essential for 
insulin-regulated GLUT4 translocation and glucose transport. It is possible that 
the F-actin changes are localized in cholesterol-enriched caveolae microdomain 
membrane regions. In vitro and in vivo imaging analyses from this study seem to 
intriguingly support the observed reciprocal changes in membrane cholesterol 
and F-actin. Notably, the F-actin labeling has been documented in electron 
micrographs to be localized in caveolae regions (469). While caveolae have been 
postulated to contribute to many functions in insulin and GLUT4 action through 
the years (17), these findings must be cautiously interpreted. Concerns regarding 
the study of caveolae are associated with each of the numerous strategic 
approaches used to study these structures. In spite of these caveats, 
fluorescence confocal labeling of caveolae and cortical F-actin have revealed 
actin filaments emanating from caveolae microdomains (74). 
Moreover, quantitative electron microscopy and freeze-fracture analyses have 
revealed that cytoskeletal components, including actin, are highly enriched in the 
membrane area underlying the neck part of caveolae (75). Together, these 
findings assign caveolae a critical role in the functionality of cortical F-actin 
organization. Given the unequivocal importance of cortical F-actin in insulin-
regulated GLUT4 translocation, these findings also emphasize the importance of 
caveolae in GLUT4 regulation. Of interest to our understanding of caveolae-
associated actin regulation are new electron microscopic data showing high 
concentrations of  PIP2 at the rim of caveolae (76). This localization of PIP2 is 
consistent with its regulation of the cytoskeleton where this lipid’s availability is 
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recognized to modulate membrane/cytoskeleton interaction, the stability of 
cortical F-actin and the turnover of cytoplasmic stress fibers (77). Interestingly, 
reduced PM PIP2 and cortical F-actin structure are observed in hyperinsulinemia-
induced insulin-resistant 3T3-L1 adipocytes and L6 myotubes. In these cell 
model systems insulin-stimulated GLUT4 translocation is impaired, but can be 
corrected with exogenous PIP2 addition to the PM that mediates a restoration of 
cortical F-actin structure (7, 78). 
 Although speculative, we view the findings presented in Chapter IIA and IIB, 
in light of fundamental findings from others, as a possible indication that 
membrane/cytoskeletal defects could negatively impinge on GLUT4 
translocation. Furthermore, these data suggest that the membrane/cytoskeletal 
defects are induced prior to those in insulin signaling. Supporting this view are 
studies using various cell model systems of insulin resistance that demonstrate 
insulin signaling to Akt2/TBC1D4 is not impaired (7, 13, 16, 19, 78, 232). 
Collectively these data point to the notion that some insulin-resistant states may 
result from a membrane/cytoskeletal-based mechanical defect in GLUT4 
vesicle/PM arrival, tethering, docking, and/or fusion. In summary, these in vitro 
studies suggest that membrane cholesterol influences cytoskeletal structure 
essential for insulin-regulated GLUT4 translocation and glucose transport. While 
intermittent study has coupled membrane fluidity to insulin sensitivity (228, 306, 
461), a mechanistic understanding has remained elusive. It is an interesting 
concept that countering membrane cholesterol toxicity may be a common 
mechanism of action of several antidiabetic agents known to activate AMPK. 
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 In Chapter IIC we aimed to begin translating our in vitro studies to an in vivo 
model of insulin resistance. Moreover, we sought to test whether early Cr3+ 
supplementation during a normal glucose tolerant state could reduce or prevent 
obesity-associated glycemic deterioration. In this regard, obesity-prone C57BL/6J 
mice provided an extremely useful model to study the development of obesity 
and insulin resistance as a result of excessive dietary fat (438-440). The results 
presented in Chapter IIC provide in vivo evidence that supports our in vitro 
findings regarding Cr3+ action in skeletal muscle. Specifically, these studies using 
a HF-fed model of insulin resistance provide important evidence that suggests 
early Cr3+ supplementation during a five week acclimation period prevents the 
negative impact of a subsequent bout of HF feeding for eight weeks.  
 While these in vivo findings improve our understanding of 
membrane/cytoskeletal aspects of insulin sensitivity and Cr3+ action in skeletal 
muscle, future studies will be required to address several key unanswered 
questions regarding these mechanisms. For example, what is the therapeutic 
window of the most efficacious Cr3+ action during the progression of insulin 
resistance? The data presented in Chapter IIC suggest that early CrPic 
supplementation prior to HF feeding can improve glucose tolerance and key 
parameters of skeletal muscle insulin sensitivity. These data provide suggestive 
evidence that CrPic may prevent skeletal muscle membrane/cytoskeletal 
derangements associated with the progression of insulin resistance. In future 
studies we will add to our eight week study by obtaining earlier (2-, 4-, and 6-
week) and later (12-, 16-, 20-, and 24-week) diet/intervention data and then test 
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the idea that Cr3+’s effectiveness depends on the state of disease progression. It 
is well established that there are multiple mechanisms of insulin resistance and 
that insulin resistance likely gives rise to other abnormalities, including 
dyslipidemia. Consequently, we reason that beneficial effects of Cr3+ are time 
dependent. Although we find Cr3+ mitigates HF-induced membrane cholesterol 
increases in skeletal muscle after eight weeks of HF feeding, we do not yet know 
how early membrane cholesterol begins to accumulate, how Cr3+ acts during this 
early period and if Cr3+ effectiveness persists during longer diet durations.  
Our working hypothesis for these studies is that membrane cholesterol 
toxicity occurs early and persists throughout the pathogenesis of disease and 
that Cr3+ is efficacious early but its efficacy is progressively lost when other 
factors (e.g., inflammatory stress, signaling defects) contribute to insulin 
resistance. We propose that secondary signaling pathways such as inflammation 
exacerbate insulin resistance through different mechanisms as compared to the 
initial membrane cholesterol insult and that these pathways are not amenable to 
Cr3+ action. Studies have suggested that HF-induced inflammatory responses 
are likely to be observed between eight and fourteen weeks in these mice (470). 
As proof of principle, we plan to test the effect of Cr3+ on established cell models 
of insulin resistance induced by adipokines (471) or cytokines (472) characteristic 
of inflammation observed in later stages of insulin resistance. Perhaps the partial 
protective effect of Cr3+ on glucose tolerance we see after eight weeks of HF 
feeding reflects skeletal muscle inflammation. In addition, our in vitro and in vivo 
data would predict that this beneficial effect of Cr3+ may be more pronounced in 
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patients treated with Cr3+ at early stages of their disease. By testing the 
prediction that later mechanisms fueling metabolic disorder decrease Cr3+ 
efficacy, we will address the limitations in the current clinical evidence and better 
define the therapeutic window during which Cr3+ supplementation is most 
effective. 
 With regard to our expectation of late stage intervention being less effective, 
this observation could explain the conclusion from the recent review of 
randomized control trials that Cr3+ supplementation in patients with existing T2D 
may offer only a slight improvement in glycemic status (289). We predict the 
slight effect is likely a consequence of an inflammatory response and subsequent 
signaling defects that occur after membrane cholesterol accrual/toxicity. This 
expectation is from the measurement of inflammation markers presenting later in 
skeletal muscle, liver and adipose tissue (470), and that insulin resistance 
measured in terms of in vivo tissue glucose handling (evident within three weeks) 
in these HF-fed mice precedes the onset of impaired insulin signaling in these 
tissues that became evident between four to eight weeks of HF feeding (473). 
Interestingly, this study found detectable changes in systemic glucose handling 
within one and a half weeks of HF feeding (473). The basis for this impairment is 
unknown, yet we predict our two-week Cr3+/diet intervention will show 
membrane/cytoskeletal derangement as a basis and that Cr3+ offers protection 
against.  
In addition, in future studies we will build upon preliminary siRNA knockdown 
data suggesting AMPK mediates Cr3+ action. We will complement our in vitro 
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analyses by testing if AMPK mediates the in vivo action of Cr3+. We have found 
that Cr3+ increases AMPK activity in 3T3-L1 adipocytes (22-24) and L6 
myotubes, and increased AMPK activity was also seen in fat and muscle from 
Cr3+-supplemented HF-fed C57Bl/6J mice. Interestingly, the most potent Cr3+-
mediated stimulation of AMPK in vitro and in vivo occurs in the insulin-resistant 
state, a clinically-advantageous aspect of Cr3+ action. To supplement our in vitro 
studies, we will validate whether our cell-based observations explain the in vivo 
benefits of Cr3+ action. To confirm that activation of muscle AMPK is required for 
the antidiabetic activity of Cr3+ in vivo, we will examine Cr3+’s activity in mice 
expressing a muscle-specific inactive AMPK. If muscle AMPK is required for 
Cr3+’s actions, we would predict that Cr3+ will be ineffective in protecting against 
insulin resistance in these mice. Mice lacking the α1 isoform present no defect in 
glucose homoeostasis (426), as assessed by the glucose tolerance test. In 
contrast, mice lacking the α2 isoform clearly exhibit reduced insulin sensitivity 
(426). More recently the role of AMPKα2 in insulin resistance development was 
studied using muscle-specific transgenic mice on a B6 background expressing 
an inactive form of the AMPKα2 catalytic subunit (427). In this study it was found 
that ablation of muscle AMPKα2 activity worsens the glucose intolerance induced 
by HF feeding. This exacerbated glucose intolerance was associated with a 
decrease in muscle glucose transport in response to insulin, measured in vitro in 
isolated muscles (427). These results demonstrate that AMPKα2 activity is an 
important factor contributing to insulin action on glucose transport in muscle. 
Using these mice we will perform future studies to determine the importance of 
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AMPK in skeletal muscle Cr3+ action. A single diet/Cr3+ treatment duration (i.e., 
either 2-, 4-, 8-, 12-, 16-, 20-, 24-weeks) will be used in these studies based on 
when we observe cholesterol accrual, insulin resistance and Cr3+ action in the 
diet intervention studies described above. 
 Finally, to characterize the distal mechanism(s) involved in Cr3+ action future 
study will assess if inhibition of the HBP and/or HMGR is a mechanism of Cr3+ 
and/or AMPK action. As described in detail above, AMPK can directly inactivate 
HMGR via phosphorylation at Ser872. We have also recently shown that 
hyperglycemia-, hyperinsulinemia-, and hyperlipidemia-induced increases in HBP 
activity lead to increased cholesterol synthesis, membrane cholesterol accrual, F-
actin loss and GLUT4 dysregulation (10, 11). Moreover, our group has 
determined that blockade of the HBP inhibited membrane cholesterol accrual, F-
actin loss and glucose transport dysfunction induced by these derangements (10, 
11), suggesting a role of O-linked glycosylation in engaging cholesterol 
synthesis. Of interest is that a recent study has demonstrated that AMPK 
phosphorylates/inhibits GFAT (449), a rate-limiting enzyme of the HBP, 
implicating the HBP as a potential downstream pathway inhibited by Cr3+ action 
via AMPK. Conversely, it has also been shown that chronic HBP activation can 
increase fatty acid oxidation by increasing phosphorylation/activation of AMPK in 
part through O-linked glycosylation of AMPK. However, this transgenic model of 
HBP activity involved overexpression of GFAT, which does not efficiently 
represent the transient physiologically-relevant nature of nutrient flux through the 
HBP (474). The various putative interactions between the HBP and AMPK 
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suggest a complex interplay exists between these nutrient sensing pathways to 
regulate nutrient flux and energy balance. Therefore, we will assess if inhibition 
of the HBP and/or HMGR is a mechanism of Cr3+ and/or AMPK action. These 
future studies will be designed to delineate the specific targets of Cr3+ action; i.e., 
although it is expected Cr3+-dependent activation of AMPK suppresses 
cholesterol synthesis via phosphorylation/inactivation of GFAT and/or HMGR, it 
is possible that Cr3+ could target these enzymes independently of AMPK. 
Therefore, we will also test the action of Cr3+ in mice expressing an inactive form 
of AMPK described above. Our working hypothesis is that Cr3+ suppresses 
pathological cholesterol synthesis by activating AMPK that either suppresses 
GFAT and/or HMGR activity driving cholesterol synthesis. Studying the status of 
the HBP and HMGR at different time periods of Cr3+/dietary intervention, as well 
as performing confirmatory studies in vitro, will importantly show whether in vivo 
Cr3+ action is associated with suppression of HBP activity and whether the 
mechanism requires AMPK.  
Since skeletal muscle is responsible for most postprandial glucose disposal 
and is regarded as a major site of insulin resistance, deepening insight into the 
effect of Cr3+ on insulin sensitivity in this tissue during health and disease will be 
significant. Identification of AMPK as a mediator of Cr3+ action may provide an 
explanation for the existing controversies over the efficacy of Cr3+ in the 
amelioration of the symptoms and complications of T2D. For example, several 
agents that normalize blood glucose concentrations and/or improve insulin 
action, including metformin (333), phenformin (475), rosiglitazone (476) and 
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troglitazone (477), have been shown to activate AMPK. Our data would predict 
that the nutritive value of Cr3+ would be masked in patients receiving metformin 
or one of the other therapies listed above. Similarly, our model would explain why 
exercise, which also activates AMPK, can improve glycemia and dyslipidemia. 
Our model in which altered glucose homeostasis and lipoprotein status is a 
consequence of elevated peripheral tissue membrane cholesterol levels 
represents a major paradigm shift in our thinking of mechanisms leading to 
insulin resistance and dyslipidemia. Discovery that Cr3+ effectively targets this 
abnormality stresses a plausible beneficial action of this micronutrient in health 
and disease. We propose the innovative concept that Cr3+ protects against 
membrane cholesterol accrual/toxicity that represents an early contributing 
feature of insulin resistance and dyslipidemia. However, in this thesis research 
we did not test if CrPic supplementation would be protective if initiated after these 
derangements were already induced. Therefore, future studies will be performed 
to define where (e.g., adipose tissue, skeletal muscle, liver, etc.) and when 
during HF induced pathology Cr3+ has a significant impact on glucose/lipoprotein 
disorders.  We aim to unambiguously determine the nutritive and 
pharmacological value of Cr3+ supplementation in managing and/or preventing 
disorders in glucose and lipoprotein metabolism. This information is absolutely 
essential for a clinically meaningful understanding of the antidiabetic and 
cardioprotective values of this micronutrient. Moreover, by broadening our basic 
scientific understanding of the mechanism of Cr3+ action, the findings will provide 
novel avenues for intervention. 
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Conclusion 
In conclusion, together the data presented in Chapter II provide novel 
mechanistic insight into the mechanisms by which Cr3+ improves skeletal muscle 
insulin sensitivity. These data have demonstrated that CrPic protects against 
hyperinsulinemia-induced GLUT4 and glucose transport regulation, as well as 
improves glucose tolerance and insulin sensitivity in a diet-induced mouse model 
of insulin resistance. In vitro and in vivo data suggest that CrPic protects against 
membrane cholesterol accrual that disrupts F-actin integrity required for efficient 
GLUT4 regulation in skeletal muscle. Mechanistically, data have shown that 
AMPK plays a causal role in CrPic’s protective effects on GLUT4 and glucose 
transport dysfunction, rather than CrPic enhancing insulin signaling mediators. 
Importantly, AMPK activation and downstream inhibition of FA and cholesterol 
synthesis machinery was also observed in skeletal muscles obtained from HF-
fed mice supplemented with CrPic. Furthermore, data presented in Chapters IIA 
and IIB show that membrane cholesterol lowering is an unappreciated aspect of 
the mechanism by which AMPK activation enhances insulin-stimulated GLUT4 
translocation to the PM in both insulin-sensitive and insulin-resistant skeletal 
muscle myotubes. Overall, these data suggest that Cr3+ has beneficial effects on 
skeletal muscle insulin sensitivity and whole body glucose tolerance by activating 
AMPK and positively impacting membrane/cytoskeletal aspects of GLUT4 
regulation. We propose that Cr3+, via AMPK activation, suppresses cholesterol 
synthesis and thereby lowers membrane cholesterol accrual that disrupts F-actin 
and induces insulin resistance in skeletal muscle. 
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Chapter IV.  Experimental procedures 
 
Cell culture and treatments 
Rat L6 muscle cells stably expressing GLUT4 that carries an exofacial myc-
epitope (L6-GLUT4myc; generously obtained from Dr. Amira Klip, (The Hospital 
for Sick Children, Toronto, Canada) were cultured as previously described. 
Myoblasts were maintained in α-Minimum essential medium (α-MEM) containing 
5.5 mM glucose (Gibco, Grand Island, NY) and 10% fetal bovine serum (FBS; 
HyClone Laboratories, Grand Island, NY), and differentiated into multinucleated 
myotubes with 2% FBS. All studies used myotubes between 4 and 6 days post-
initiation of differentiation. Cells were serum starved for 30 min before all 
experiments. Note longer serum starvation periods we tested did not enhance 
the characteristic low response (1.5-2.0 fold) of this cell line to insulin. Cells were 
then left untreated or treated with Cr3+ (CrPic, 16 h, 100 nM, Nutrition 21) or 
zaragozic acid A (16 h, 10 µM, Sigma-Aldrich). In a separate set of experiments, 
cells were left untreated or treated with 1 mM AICAR for 45 min or 200 μM DNP 
for 30 min. During the final 20 min (or 5 min for insulin signaling analyses) of 
these incubations, cells were left in either the basal state or were acutely 
stimulated with 100 nM insulin. In a subset of experiments, insulin induction of 
insulin resistance was performed as previously described (8) by treating the cells 
with 5 nM insulin for 12 h. 
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Mice 
Male C57BL/6J mice (age 4 weeks) were obtained from Jackson Labs and 
housed in a light/temperature-controlled animal room maintained on a 12-h light, 
12-h dark cycle. The mice were fed ad libitum NIH standard chow and water for 
one week, fed the LF diet for three weeks to acclimate to the increased palm oil 
in the diet, and then divided into treatment groups. Based on the fact commercial 
Cr3+-containing nutritional supplements generally contain 200 to 600 µg Cr3+ and 
an average human body mass of 70 kg, the supplements provide ~3 to 9 µg 
Cr3+/kg body weight/day. In these studies we administered 8 µg Cr3+/kg body 
weight/day (CrPic; Nutrition 21, Purchase, NY) dissolved in the drinking water to 
control and high-fat fed C57Bl/6J mice. Control mice received a diet containing 
20% kcal from protein, 70% kcal from carbohydrates, and 10% kcal from fat 
(D01030107, Research Diets Inc., New Brunswick, NJ). High-fat fed mice 
received a diet containing 20% kcal from protein, 35% kcal from carbohydrates, 
and 45% kcal from fat (D01030108, Research Diets Inc., New Brunswick, NJ). 
These diets were modified forms of D12450B and D12451 diets, with adaptations 
regarding type of fat (palm oil instead of lard) and carbohydrates to better mimic 
the FA/carbohydrate composition of the average human diet in Western 
societies, and induce significant insulin resistance in C57Bl/6J mice (445). The 
modified HF diet mimics the ratio of saturated to monounsaturated to 
polyunsaturated FAs (40:40:20). [For simplicity I refer to these diets as LF and 
HF]. In addition, these diets were made with a Cr3+-free mineral mix (S17902) 
and Avicel PH101 (instead of cellulose, which contains Cr3+). By addition of 
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chromium potassium sulfate, to the Cr3+-free diets, both the LF and HF test diets 
were controlled to contain an equal amount of Cr3+. Note the energy density of all 
nutrients, except fat and starch, is equal. All in vivo procedures performed using 
mice were based on protocols approved by the Indiana University School of 
Medicine Institutional Animal Care and Use Committee. 
 
Rats 
 Specific pathogen-free obese (fa/fa) and lean (Fa/?) female Zucker rats were 
obtained from Harlan Sprague-Dawley at 6 weeks of age. Upon arrival, rats were 
housed individually in a temperature-controlled animal room maintained on a 
12:12-h light-dark cycle. The rats were fed ad libitum NIH standard chow and 
water. All in vivo procedures performed were based on protocols approved by the 
Eli Lilly Institutional Animal Care and Use Committee. 
 
IPGTT 
C57Bl/6J mice were fasted for 6 hours (from 8:00 a.m. to 2:00 p.m.) in all 
IPGTT studies. Mice were injected intraperitoneally with 2 g/kg D-glucose 
(individually-dosed) at time 0 and blood was obtained via tail blood collection at 
15 min, 30 min, 60 min, 90 min and 120 min post-injection of glucose.  Blood 
glucose was analyzed using the Abbott Animal Health AlphaTRAK blood glucose 
meter (Abbott Laboratories, Abbott Park, IL). 
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IPITT 
C57Bl/6J mice were fasted for 6 hours (from 8:00 a.m. to 2:00 p.m.) before all 
IPITT studies. Mice were injected intraperitoneally with 1.0 unit of insulin per kg 
body weight (individually-dosed) at time 0 and blood was obtained via tail blood 
collection at 15 min, 30 min, 60 min, 90 min and 120 min post-injection of insulin. 
Blood glucose was analyzed using the Abbott Animal Health AlphaTRAK blood 
glucose meter (Abbott Laboratories, Abbott Park, IL). 
 
Immunocytochemistry 
Myotube GLUT4myc and F-actin labeling was performed as previously 
described (8). Briefly, myotubes were fixed with 2% paraformaldehyde/phosphate 
buffered saline (PBS). After fixation, cells were either left unpermeabilized 
(GLUT4myc) or were permeabilized (F-actin) for 15 min at room temperature in 
0.2% Triton X-100/PBS (actin for Li-Cor). Cells were then blocked for 1 h at room 
temperature in Odyssey Blocking Buffer (Li-Cor Biosciences, Lincoln, NE). The 
samples were then incubated in primary antibody overnight, washed and 
incubated with an infrared-conjugated secondary antibody (Li-Cor) or with 1:50 
FITC-conjugated anti-mouse (confocal) for 1 h. Images were collected and 
quantified with the Odyssey system as previously described (8). 
Immunofluorescent intensity was normalized to intensity from Syto60, a 
fluorescent nucleic acid stain (Molecular Probes).  
C57BL/6J soleus muscle was prepared and labeled as previously described. 
Briefly, following an overnight fast soleus muscles were dissected out, blotted on 
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gauze, quickly rinsed with PBS, and immersed in 4% paraformaldehyde/PBS. 
Following fixation for 2 h, tissues were washed with PBS then permeabilized for 
20 min at room temperature in 0.2% Triton X-100/0.05% Tween 20/PBS. Tissues 
were rinsed three times in PBS then blocked in 5% donkey serum for 60 min at 
room temperature. Tissues were then incubated overnight at 4°C in anti-F-actin 
antibody diluted 1:50 in blocking buffer. Samples were washed extensively in 
PBS before incubation for 60 min at room temperature in 1:50 rhodamine red-X-
conjugated donkey anti-mouse IgM. Secondary antibody incubations were 
followed by extensive washing in PBS then a quick ddH2O rinse. Tissues were 
mounted in slides with Vectashield and were analyzed via confocal microscopy 
(model LSM 510 NLO; Zeiss, Thornwood, NY). 
Rat skeletal muscle was prepared and labeled as previously described (8, 
18). Briefly, after 2 weeks of acclimation, rats in the postprandial state were 
anesthetized with 5 mg/100 g body weight sodium pentobarbital and the 
epitrochlearis muscles were dissected out, blotted on gauze, quickly rinsed in 
saline and immersed in 4% paraformaldehyde/PBS. Both epitrochlearis muscles 
from five lean and 5 obese rats were used, for a total of ten muscles. Myotube 
and skeletal muscle images were obtained using the Zeiss LSM 510 NLO 
Confocal Microscope. For all confocal imaging, all microscopic and camera 
settings were identical within experiments, and representative images are shown. 
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Insulin ELISA 
 Blood was collected by cardiac puncture in the prandial state. Plasma was 
obtained by centrifuging blood samples at 4°C for 15 min at 2000 rpm using a 
table top centrifuge. Plasma insulin concentrations were determined using the 
Ultra Sensitive Mouse Insulin ELISA Kit (Crystal Chem Inc., Downers Grove, IL).  
 
ATP measurement 
 Intracellular ATP content was measured using a luminescence ATP detection 
assay system (ATPliteTM, PerkinElmer Inc.). Briefly, following experimental 
treatments, L6 myotubes were lysed using a mammalian cell lysis buffer which 
inactivates endogenous ATPase. Subsequently whole cell lysate was incubated 
with substrate buffer and luminescence was detected using the SpectraMax M2 
(Molecular Devices). Luminescence was converted to actual ATP content (nM) 
by use of an ATP standard curve. ATP concentrations were normalized for 
protein concentration determined by the Bradford method. 
 
Membrane and cholesterol analyses 
A plasma membrane-enriched fraction was prepared as described by Khayat 
et al. (437). Briefly, myotube monolayers grown on 10-cm-diameter dishes were 
gently scraped with a rubber policeman in 5 ml of ice-cold HES homogenization 
buffer (in mM: 250 sucrose, 20 HEPES, 2 EGTA, and 3 NaN3, pH 7.4) containing 
freshly added protease inhibitors (in µM: 200 PMSF, 1 leupeptin and 1 pepstatin 
A) and homogenized through a 22-gauge needle 10 times. The homogenate was 
centrifuged at 760 g for 5 min at 4°C, and the resultant supernatant was 
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centrifuged at 31,000 g for 20 min to separate a plasma membrane-enriched 
pellet from an intracellular microsome supernatant. The plasma membrane pellet 
was resuspended in HES buffer and assayed for protein (Bradford) and 
cholesterol (Amplex Red) content as previously described (22, 23). Several 
unpublished analyses we have performed revealed that measured changes in 
plasma membrane cholesterol were similarly reflected in total cellular membrane 
fractions prepared by centrifuging the original cellular homogenate at 5,000 g for 
20 min at 4°C and then subjecting the supernatant to centrifugation at 100,000 g 
for 30 min. As the number of 10-cm-diameter dishes required to obtain this total 
membrane fraction was half that required to prepare plasma membrane-enriched 
fractions we used total membrane fractions in the current study. 
The preparation of βCD-cholesterol complex was performed essentially by 
the method of Christian et al. (478), with minor modifications. Briefly, 96.7 µl of 
cholesterol from 5 mg/ml stock in chloroform-methanol (1:1, vol:vol) was added 
to a glass tube. The solvent was evaporated under a gentle stream of nitrogen 
gas, and a dried cholesterol film was formed on the bottom of the tube. Next, 10 
ml of 1 mM βCD was added, vortexed and sonicated (bath sonicator), resulting in 
a solution containing βCD to cholesterol at a ratio of 8:1. This 100% saturated 
βCD-cholesterol solution was incubated in a 37°C water bath for 48 h with 
vigorous shaking. This mixed solution was then filtered through a 0.45-µm 
syringe filter (Millipore) before use. In the cholesterol replenishment experiments, 
during the 30-min serum starvation period cells were pre-incubated with this 
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solution prior to treatments with AICAR, DNP, and/or insulin. All treatments were 
performed during continual exposure to the βCD-cholesterol solution. 
 
2-Deoxyglucose uptake assays 
Following treatments, cells were incubated in glucose-free buffer (125 mM 
NaCl, 5 mM KCl, 1.8 mM CaCl2, 2.6 mM MgSO4, 25 mM HEPES, 2 mM pyruvate 
and 2% BSA) for 30 min, then either left in the basal state or stimulated with 100 
nM insulin for 20 min. Glucose uptake was initiated with the addition of 2-deoxy-
[1,2-3H]-glucose (0.055 µCi/µl). Nonspecific uptake was quantitated via cell-
associated radioactivity in the presence of 20 µM cytochalasin B. After 10 min, 
uptake was terminated via four quick washes with ice-cold PBS. Cells were 
solubilized in 1 N NaOH and [3H] was measured by liquid scintillation. Counts 
were normalized to total cellular protein, as determined by the Bradford method.  
 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
analyses 
Total cell extracts were prepared from 10-cm-diameter dishes. Myotubes 
were washed two times with ice-cold PBS and scraped into 1 ml lysis buffer (25 
mM Tris, pH 7.4, 50 mM NaF, 10 mM Na3P2O7, 137 mM NaCl, 10% glycerol and 
1% Nonidet P-40) containing 2 mM PMSF, 2 mM Na3VO4, 5 µg/ml aprotinin, 10 
µM leupeptin and 1 µM pepstatin A then rotated for 15 min at 4°C. Insoluble 
material was separated from the soluble extract by centrifugation for 15 min at 
4°C. Protein concentrations were determined via the Bradford method and 
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equivalent protein amounts were separated by 7.5% SDS-PAGE. The resolved 
fractions were transferred to nitrocellulose (Bio-Rad, Hercules, CA). Phospho-
Akt-2 was detected with anti-phospho-Akt-2 (Ser474) (Genscript, Piscataway, 
NJ). Phospho-IR and IRS1 were detected with a monoclonal phosphotyrosine 
antibody (PY20; Transduction Laboratories, San Diego, CA). We also used 
phosphospecific antibodies to AMPK and AS160 (Cell Signaling Technology, 
Danvers, MA) and to HMGR and ACC (Millipore, Temecula, CA). Equal protein 
loading was confirmed by Ponceau staining and by immunoblot analysis with 
anti-ACC and anti-AMPK (Cell Signaling Technology, Danvers, MA), and anti-
actin antibody (Cytoskeleton, Denver, CO). All immunoblots were labeled with IR-
conjugated secondary antibodies and analyzed via the Odyssey system (Li-Cor, 
Lincoln, NE). 
 
siRNA design and transfection 
 Three independent oligonuceotide sequences, designed and purchased from 
Ambion (Austin, TX), were tested for each of the two alpha subunit isoforms. The 
oligonucleotides with the highest knockdown efficiency for α1 and α2 were 
respectively: CGA GUU GAC UGG ACA UAA Att (siRNA ID#: 194424) and GCA 
ACU AUC AAA GAC AUA Ctt (siRNA ID#: 194794). As these cells express both 
alpha isoforms, the combination of the two nucleotides led to the greatest 
knockdown efficiency. Ambion’s Negative Control #1 siRNA (Cat #:4635) was 
used as a control in all experiments. For all knockdown experiments cells were 
seeded as described before. Cells were first transfected at approximately 48 hr 
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post seeding (or ~60% confluency). Calcium phosphate transfection protocol was 
utilized as follows, 60 pmol of siRNA was added to siRNA mix: 15 µl ddH2O, 15 
µl Buffer A (0.5 M CaCl2, 0.1 M HEPES (pH 7.0)), and 30 µl Buffer B (0.28 M 
NaCl, 0.75 mM NaH2PO4, 0.75 mM Na2HPO4, 0.05 M HEPES (pH 7.0)) and after 
10 min at room temperature, the siRNA mix was added to each well of a 12 well 
plate containing 600 µl Dulbecco’s modified Eagle’s medium (DMEM) + 5% FBS 
and incubated 12-16 hr. Following 12-16 hr incubation, media was aspirated and 
replaced with DMEM + 2% FBS. Additional transfection was repeated 72 hr after 
initial transfection. Cells were treated and assayed 72 hr after final transfection. 
 
Statistics 
 All values are presented as means ±SE. The significance of differences 
between means was evaluated by one-way repeated measures analysis of 
variance (ANOVA). Where differences among groups were indicated, the 
Newman-Keuls test was used for post hoc comparison between groups. 
Differences between two groups were analyzed by the Student’s t-test for 
independent samples. GraphPad Prism 4 software was used for all analyses. P < 
0.05 was considered significant. 
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